PUBLICATIES

betreffende BOOG-studies

maart 2025

Publicaties betreffende BOOG-studies

Inhoud

BOOG 2001-01 / TEAM

Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial
Zhang X, Gunda A, Meershoek-Klein Kranenbarg E, Liefers GJ, Savitha BA, Shrivastava P, Serkad CPVK, Kaur T, Eshwaraiah MS, Tollenaar RAEM, van de Velde CJH, Seynaeve CMJ, Bakre M, Kuppen PJK.
Breast Cancer Res. 2023 Apr 14;25(1):40. doi: 10.1186/s13058-023-01643-2.

Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer.
Lee Meeuw Kjoe PR, Kieffer JM, Small BJ, Boogerd W, Schilder CM, van der Wall E, Meershoek-Klein Kranenbarg E, van de Velde CJH, Schagen SB.
JNCI Cancer Spectr. 2023 Mar 1;7(2):pkad022. doi: 10.1093/jncics/pkad022.

Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer.
Xu K, Bayani J, Mallon E, Pond GR, Piper T, Hasenburg A, Markopoulos CJ, Dirix L, Seynaeve CM, van de Velde CJH, Rea DW, Bartlett JMS.
J Mol Diagn. 2022 Jul;24(7):775-783. doi: 10.1016/j.jmoldx.2022.04.002. *Epub 2022 May 5.*

Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study.
Bartlett JMS, Bayani J, Kornaga E, Xu K, Pond GR, Piper T, Mallon E, Yao CQ, Boutros PC, Hasenburg A, Dunn JA, Markopoulos C, Dirix L, Seynaeve C, van de Velde CJH, Stein RC, Rea D.
NPJ Breast Cancer. 2021 Jul 8;7(1):90. doi: 10.1038/s41523-021-00297-7.

The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival.
D Houtsma, S de Groot, R Baak-Pablo, E Meershoek -Klein Kranenbarg, CM Seynaeve, CJ H van de Velde, S Böhringer, JR Kroep, H Guchelaar, H Gelderblom
Scientific Reports. (2021)

Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
Noordhoek I, Blok EJ, Meershoek-Klein Kranenbarg E, Putter H, Duijm-de Carpentier M, Rutgers EJT, Seynaeve C, Bartlett JMS, Vannetzel JM, Rea DW, Hasenburg A, Paridaens R, Markopoulos CJ, Hozumi Y, Portielje JEA, Kroep JR, van de Velde CJH, Liefers GJ.J
Clin Oncol. 2020 Oct 1;38(28):3273-3281. doi: 10.1200/JCO.19.02427. Epub 2020 Jul 24.

Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine.
Bayani J, Yao CQ, Quintayo MA, Yan F, Haider S, D'Costa A, Brookes CL, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea D, Boutros PC, Bartlett JMS.
NPJ Breast Cancer. 2017 Feb 15;3:3.

The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis.

Engels CC, de Glas NA, Sajet A, Bastiaannet E, Smit VT, Kuppen PJ, Seynaeve C, van de Velde CJ, Liefers GJ.
Mol Oncol. 2016 Apr;10(4):509-16.

Physical Functioning in Older Patients With Breast Cancer: A Prospective Cohort Study in the TEAM Trial.
Derks MG, de Glas NA, Bastiaannet E, de Craen AJ, Portielje JE, van de Velde CJ, van Leeuwen FE, Liefers GJ.
Oncologist. 2016 Aug;21(8):946-53.

Variation in the *ESR-1* gene as a prognostic marker in early breast cancer survival.
Danny Houtsma, Stefanie de Groot, Tahar van der Straaten, Renee Baak-Pablo, Cock J.H. van der Velde, Henk-Jan Guchelaar, Hans Gelderblom
ASCO 2014

Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.
Bartlett JM, Christiansen J, Gustavson M, Rimm DL, Piper T, de Velde CJ, Hasenburg A, Kieback DG, Putter H, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW.
Arch Pathol Lab Med. 2016 Jan;140(1):66-74.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde CJH, Pan H, Peto R, Davies C, Gray R.
Lancet. 2015 Oct 3;386(10001):1341-52.

S4-06. HER2 status as predictive marker for AI vs Tam benefit: a TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Bartlett JMS et al.
(2015) SABCS

P2-08-29. Defining a signature of residual risk following endocrine treatment in the tamoxifen and exemestane adjuvant multinational (TEAM) trial.
Bayani J et al.
(2015) SABCS

Does androgen receptor (AR) expression impact on residual risk? A TEAM pathology study
John MS Bartlett, Cassandra L Brookes, Fu J Yan, Mary Anne Quintayo, Jane Bayani, Jane Starczynski, Cornelis JH van de Velde, Annette Hasenburg, Dirk G Kieback, Christos Markopoulos, Luc Dirix, Caroline Seynaeve and Daniel W Rea
SABCS 2014, publication number P4-11-05

PIK3CA Mutations Are Linked to PgR Expression: A Tamoxifen Exemestane Adjuvant Multinational (TEAM) Pathology Study.
Sabine VS, Crozier C, Drake C, Piper T, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea D, Bartlett JMS
SABCS 2012

Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients.
DBY Fontein, D Houtsma, ETM Hille, C Seynaeve, H Putter, E Meershoek-Klein Kranenbarg, HJ Guchelaar, H Gelderblom, LY Dirix,R Paridaens, JMS Bartlett, JWR Nortier, CJH van de Velde, on behalf of the Dutch TEAM steering committee.
(2012) Ann Oncol, Aug 2 [Epub ahead of print]

Influence of semi-quantitative estrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – a TEAM study analysis.
W van de Water and DBY Fontein, JGH van Nes, JMS Bartlett, ETM Hille, H Putter, T Robson, GJ Liefers, RMH Roumen, C Seynaeve, LY Dirix, R Paridaens, E Meershoek-Klein Kranenbarg, JWR Nortier, CJH van de Velde
(2012) European Journal of Cancer, accepted July 2012

Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.
van de Water W, Markopoulos C, van de Velde CJH, Seynaeve C, Hasenburg A, Rea D, Putter H, Nortier JW, de Craen AJ, Hille ETM, Bastiaannet E, Hadji P, Westendorp RG, Liefers GJ, Jones SE JAMA. *2012 Feb 8; 307(6): 590-7*

Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis.
van de Water W, Bastiaannet E, Hille ETM, Meershoek-Klein Kranenbarg E, Putter H, Seynaeve CM, Paridaens R, de Craen AJ, Westendorp RG,Liefers GJ, van de Velde CJH.
Oncologist. 2012; 17(1):55-63. Epub 2022 Dec 30.

Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors – a TEAM trial analysis.
Duveken BY Fontein, Peyman Hadji, Caroline Seynaeve, Annette Hasenburg, Robert Paridaens, Jean-Michel Vannetzel, Christos Markopoulos, Stephen E Jones, Daniel Rea, Cornelis JH van de Velde.
(2012) Presentatie ESSO 2012, 19-21 september, Valencia

Heterogeneous HER2 Gene Amplification Impact on Patient Outcome and a Clinically Relevant Definition.
Bartlett AI, Starcyznski J, Robson T, MacLellan A, Campbell FM, van de Vekle CJH, Hasenburg A, Markopoulos C, Seynaeve C, Rea D, Bartlett JMS
*(2011) American Journal of Clinical Pathology **136** (2): 266-274*

Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial.
Bartlett JMS, Brookes CL, Robson T, van de Velde CJH, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ETM, Kay C, Kieback DG, Putter H, Markopoulos C, Meershoek-Klein-Kranenbarg E, Mallon EA, Dirix L, Seynaeve C, Rea D
*(2011) Journal of Clinical Oncology **29** (12): 1531-1538*

Efficacy of endocrine therapy regimens in major histological subtypes of breast cancer – TEAM study analysis.

Fontein DBY, van de Water W, Bartlett JMS, Liefers GJ, Markopoulos C, Seynaeve C, Meershoek-Klein-Kranenbarg E, Rea D, Jones SE, Hille ETM, Putter H, Roumen RMH, Nortier JWR, van de Velde CJH
(2011) Ejc Supplements

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.
Hadji P, Asmar L, van Nes JGH, Menschik T, Hasenburg A, Kuck J, Nortier JWR, van de Velde CJH, Jones SE, Ziller M
*(2011) Journal of Cancer Research and Clinical Oncology **137** (6): 1015-1025*

Effects of exemestane or tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis.
Hadji P, Asmar L, van Nes JG, Menschik T, Hasenburg A, Kuck J, Nortier H, Jones S, Van der Velde C, Ziller M
*(2011) Breast **20** S70*

The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
Hozumi Y, Suemasu K, Takei H, Aihara T, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y
*(2011) Annals of Oncology **22** (8): 1777-1782*

Age specific competing mortality in breast cancer patients – a TEAM study analysis.
Markopoulos C, van de Water W, Putter H, Seynaeve C, Hasenburg A, Rea D, Vannetzel JM, Paridaens R, van de Velde CJH, Jones SE
(2011) Ejc Supplements

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Van de Velde CJH, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ETM, Kieback DG, Asmar L, Smeets J, Nortier JWR, Hadji P, Burdett JMS, Jones SE
*(2011) Lancet **377** (9762): 321-331*

Specific Adverse Events and Outcome in Hormone Receptor Positive Breast Cancer Patients on Endocrine Therapy – a TEAM Study Analysis.
Van de Water W, Hille ETM, Hadji P, Markopoulos C, Seynaeve C, Hasenburg A, Dirix L, Rea D, Jones SE, van de Velde CJH
(2011) Ejc Supplements

Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy.
Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y
*(2010) Oncology **79** (5-6): 376-381*

Is 5-50% of Amplified Cells a Suitable Cut Off To Define Heterogeneous Amplification of the HER2 Oncogene?
Bartlett AI, Starcyznski J, Robson T, van de Velde CJH, Hasenburg A, Markopoulos C, Rea DW,

Campbell FM, Bartlett JMS
*(2010) Cancer Res **70** (24 Suppl)*

Final Results of a Prospectively Planned Biomarker Analysis: HER1-3 as Predictive Markers of Benefit from Early Treatment with Aromatase Inhibitors Versus Tamoxifen in the TEAM Pathology Sub-Study.
Bartlett JMS, Brookes CL, van de Velde CJH, Stocken D, Campbell FM, Hasenburg A, Kay C, Kieback D, Markopoulos C, Meershoek-Klein-Kranenbarg E, Mallon EA, Dirix L, Robson T, Seynaeve C, Rea DW
*(2010) Cancer Res **70** (24 Suppl)*

Mammostrat® as an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in Postmenopausal Early Breast Cancer: Preliminary Data of the TEAM Pathology Study.
Bartlett JMS, Bloom KJ, Goldstein NS, van de Velde CJH, Ross DT, Seitz RS, Beck RA, Hasenburg A, Kieback D, Putter H, Markopoulos C, Dirix L, Robson T, Seynaeve C, Rea DW
*(2010) Cancer Res **70** (24 Suppl)*

An Integration of Biological and Pathological Marker Panel in the TEAM Pathology Sub-Study: The Impact of Different Parameters on Risk Estimation of Relapse at Both 2.75 and 5 Years.
Bartlett JMS, Stocken D, van de Velde CJH, Brookes CL, Robson T, Hasenburg A, Hille ETM, Kieback D, Markopoulos C, Mallon EA, Dirix L, Campbell FM, Seynaeve C, Rea DW
*(2010) Cancer Res **70** (24 Suppl)*

A Comparison between AQUA Quantitative Fluorescent Immunohistochemistry and Conventional Immunohistochemistry for Hormone Receptors.
Bartlett JMS, Gustavson M, Stocken D, Rimm D, Christiansen J, van de Velde CJH, Hasenburg A, Kieback D, Putter H, Brookes C, Markopoulos C, Dirix L, Robson T, Seynaeve C, Dolled-Filhart M, Jones C, Graves L, McGuire J, Rea D
*(2010) Cancer Res **70** (24 Suppl)*

Pharmacogenetics of tamoxifen in relation to disease-free survival in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentje VO, van Schaik RH, Vletter-Bogaartz JM, Wessels JA, Hille ETM, Seynaeve C, van de Velde CJH, Nortier JWR, Gelderblom H, Guchelaar HJ
*(2010) Journal of Clinical Oncology **28** (15s)*

Effects of Exemestane or Tamoxifen on Bone Health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial: A Meta-Analysis.
Hadji P, Asmar L, van Nes J, Menschik T, Hasenburg A, Kuck J, Nortier H, Jones S, van de Velde CJH, Ziller M
*(2010) Cancer Res **70** (24 Suppl)*

Effects of Exemestane Or Tamoxifen on Bone Health Within the Tamoxifen Exemestane Adjuvant Multinational (Team) Trial: A Meta-Analysis.
Hadji P, Asmar L, van Nes J, Menschik T, Hasenburg A, Kuck J, Nortier H, Jones S, van de Velde C, Ziller M
*(2010) Annals of Oncology **21** 81-82*

Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer.
Hasenburg A, van de Velde CJH, Seynaeve C, Rea DW, Vannetzel J, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Jones SE
*(2010) Ejc Supplements **8** (3): 62*

TEAM-studie: gelijkwaardige overleving door zowel monotherapie als sequentiële therapie.
Hille ETM
*(2010) Oncologie Up-to-Date **1** (1): 3-4*

Adjuvante endocriene therapie met exemestaan of de sequentie van tamoxifen, gevolgd door exemestaan bij postmenopauzale vrouwen met hormoongevoelige borstkanker.
Hille ETM, Seynaeve C, Nortier JWR, van de Velde CJH
*(2010) Nederlands Tijdschrift voor Oncologie **7** (7): 304-309*

The effect of exemestane and anastrozole on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: final results of 3 years after randomization of N-SAS (national surgical adjuvant study) BC04, the TEAM Japan sub-study.
Hozumi Y, Aihara T, Suemasu N, Takei H, Takehara M, Masuda N, Ohashi Y
*(2010) Ejc Supplements **8** (3): 165*

Competing Causes of Mortality vs. Breast Cancer Mortality at 5-Years among 9766 Postmenopausal Women with Hormone Receptor Positive Early Breast Cancer Treated on the TEAM Study of Adjuvant Hormonal Therapy.
Jones, S. E., Putter, H., Hasenburg, A., van de Velde, C. J. H., Rea, D. W., Vannetzel, J. M., Paridaens, R., Markopoulos, C., Hozumi, Y., and Seynaeve C.
(2010) Cancer Res 70[24 Suppl]. 15-12-2010. Ref Type: Internet Communication

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: Results of a prospective gynecological ultrasound substudy.
Kieback DG, Harbeck N, Bauer W, Hadji P, Weyer G, Menschik T, Hasenburg A
*(2010) Gynecologic Oncology **119** (3): 500-505*

Distant Recurrences at Median of 5-Years Among 9.779 Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Treated on the Team Trial of Adjuvant Endocrine Therapy.
Nortier H, Hille E, Rea D, Seynaeve C, Hasenburg A, Vannetzel J, Dirix L, Markopoulos C, van de Velde C, Jones S
*(2010) Annals of Oncology **21** 78*

Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial.
Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, de Velde CJV, van Dam FS, Schagen SB
*(2010) Journal of Clinical Oncology **28** (8): 1294-1300*

Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.
Schilder CMT, Seynaeve C, Linn SC, Boogerd W, Beex LVAM, Gundy CM, Nortier JWR, van de Velde CJH, Van Dam FSAM, Schagen SB
*(2010) Critical Reviews in Oncology Hematology **76** (2): 133-141*

The Impact of Body Mass Index (BMI) on the Efficacy of Adjuvant Endocrine Therapy in Postmenopausal Hormone Sensitive Breast Cancer (BC) Patients; Exploratory Analysis from the TEAM Study.
Seynaeve C, Hille ETM, Hasenburg A, Rea D, Markopoulos C, Hozumi Y, Putter H, Nortier HWR, van Nes JGH, Dirix L, van de Velde CJH
*(2010) Cancer Res **70** (24 Suppl)*

Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
Van de Velde CJH, Verma S, van Nes JGH, Masterman C, Pritchard KI
*(2010) Cancer Treatment Reviews **36** (1): 54-62*

Discontinuation during Tamoxifen in the Sequential Arm of the TEAM Trial of Adjuvant Endocrine Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer: The Effect of IES Results and Subsequent Therapy.
Van de Velde CJH, Hille ETM, Rea D, Seynaeve C, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Kieback DG, Asmar L, Smeets J, Nortier JWR, Hadji P, Bartlett JMS, Putter H, Jones SE
*(2010) Cancer Res **70** (24 Suppl):*

Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries.
Van Nes JGH, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJH
*(2010) British Journal of Surgery **97** (5): 671-679*

Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
Van Nes JGH, Seynaeve C, Maartense E, Roumen RMH, de Jong RS, Beex LVAM, Meershoek-Klein-Kranenbarg E, Putter H, Nortier JWR, van de Velde CJH
*(2010) Annals of Oncology **21** (5): 974-982*

Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients.
Voskuil DW, van Nes JGH, Junggeburt JMC, van de Velde CJH, Van Leeuwen FE, De Haes JCJM
*(2010) Annals of Oncology **21** (10): 2094-2101*

The TEAM Trial Pathology Study Identifies Potential Prognostic and Predictive Biomarker Models for Postmenopausal Patients Treated with Endocrine Therapy.
Bartlett JMS, Brookes C, Robson T, van de Velde CH, Billingham LJ, Campbell FM, Quintayo MA, Lyttle N, Hasenburg A, Hille ETM, Kieback D, Putter H, Markopoulos C, Meershoek-Klein-Kranenbarg E, Paridaens R, Seynaeve C, Mallon EA, Rea DW
*(2009) Cancer Research **69** (24): 503S*

Estrogen and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane

adjuvant multinational (TEAM) trial.
Bartlett JMS, Brookes CL, de Velde CJHV, Billingham LJ, Hasenberg A, Markopoulos C, Mallon EA, Paridaens R, Seynaeve C, Rea DW
*(2009) Ejc Supplements **7** (2): 264*

A prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifen.
Bartlett JMS, Brookes CL, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ETM, Kay C, Kieback D, Markopoulos C, Meershoek-Klein-Kranenbarg E, Mallon EA, Paridaens R, Robson T, Seynaeve C, van de Velde CJH, Rea D
*(2009) Cancer Research **69** (2): 83S*

Preliminary Comparison between AQUA and Centralised ER/PgR Analysis within the TEAM Pathology Study.
Bartlett JMS, Rimm D, Brookes CL, Dolled-Filhart M, Robson T, van de Velde CH, Billingham LJ, Campbell FM, Hasenburg A, Hille ETM, Kieback D, Putter H, Markopoulos C, Christiansen J, Gustavson M, Mallon EA, Kranenburg EMK, Parideans R, Seynaeve C, Rea DW
*(2009) Cancer Research **69** (24): 660S-661S*

Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer.
Dezentje VO, Guchelaar HJ, Nortier JWR, van de Velde CJH, Gelderblom H
*(2009) Clinical Cancer Research **15** (1): 15-21*

Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: The TEAM Trial Experience.
Faratian D, Kay C, Robson T, Campbell FM, Grant M, Rea D, Bartlett JMS
*(2009) Histopathology **55** (5): 587-593*

The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Hadji P, Ziller M, Kieback DG, Menschik T, Kalder M, Kuck J, Hasenburg A
*(2009) Breast **18** (3): 159-164*

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.
Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen HW, Menschik T, Kuck J, Melchert F, Hasenburg A
*(2009) Annals of Oncology **20** (7): 1203-1209*

Bone effects of exemestane vs. tamoxifen within the TEAM trial: results of a prospective randomized bone sub study.
Hadji P, Ziller M, Kieback D, Dornoff W, Tessen HW, Kuck J, Hasenburg A
*(2009) Cancer Research **69** (2): 149S*

Eerste resultaten van de TEAM-studie.
Hille ETM
*(2009) Oncology News International **3** (1): 3-5*

Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase Ill trial in hormone sensitive

postmenopausal early breast cancer.
Jones SE, Seynaeve C, Hasenburg A, Rae D, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Kieback D, Asmar L, Smeets J, Urbanski R, Bartlett JMS, van de Velde CJH
*(2009) Cancer Research **69** (2): 67S*

Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy.
Markopoulos C, Polychronis A, Dafni U, Koukouras D, Zobolas V, Tzorakoleftherakis E, Xepapadakis G, Gogas H
*(2009) Annals of Oncology **20** (1): 49-55*

Aromatase inhibitors in the management of early breast cancer: The TEAM trial.
Markopoulos C
*(2009) Ejso **35** (3): 333*

Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.
Rea D, Hasenburg A, Seynaeve C, Jones SE, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Asnar L, Urbanski R, van de Velde CH, Bartlett JMS, Smeets J, Kieback DG
*(2009) Cancer Research **69** (24): 487S*

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer: results from the TEAM trial neuropsychological side study.
Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Huizenga HM, Nortier JW, van der Velder CJ, van Dam FS, Schagen SB
*(2009) Cancer Research **69** (2): 146S*

Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study.
Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, van Dam FS, Schagen SB
*(2009) Acta Oncologica **48** (1): 76-85*

Different effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer: results from the Dutch TEAM neuropsychological side study. Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB
*(2009) Ejc Supplements **7** (2): 264*

Tamoxifen and exemestane adjuvant multinational (TEAM) trial; findings from the Dutch/belgian subset.
Seynaeve C, van de Velde CJH, Maartense E, Roumen RMH, Nortier JWR, Hille ETM, van Nes JGH, Putter H, Paridaens R, Dirix LY
*(2009) Ejc Supplements **7** (2): 300*

Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer.
Van de Velde C, Seynaeve C, Hasenburg A, Rea D, Vannetzel JM, Paridaens R, Markopoulos C,

Smeets J, Nortier JWR, Jones SE
*(2009) Ejc Supplements **7** (3): 1*

Patterns of care in postmenopausal early breast cancer patients participating in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study: variations in locoregional therapy between different countries.
Van Nes JGH, Seynaeve C, Jones S, Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Markopoulos C, Meershoek-Klein-Kranenbarg E, van de Velde CJH
*(2009) Ejc Supplements **7** (2): 301*

Effect of exemestane on bone turnover markers and bone mineral density (BMD): 2 year results of the Dutch/Belgian Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Van Nes JGH, Papapoulos SE, Braun JJ, Dirix L, Putter H, Zwaan RE, Ballieux BEP, van Rongen I, van de Velde CJH, Seynaeve C, Nortier JWR
*(2009) Cancer Research **69** (2): 152S-153S*

Quality of life in relation to hormonal treatment of postmenopausal women in the Dutch Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Van Nes JGH, Voskuil DW, van Leeuwen RE, Junggeburt JMC, De Haes HCJM, van de Velde CJH
*(2009) Cancer Research **69** (2): 69S*

Physical activity to maintain quality of life in breast cancer survivors in the Dutch Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Voskuil DW, van Nes JG, Junggeburt JM, Van Leeuwen FE, van de Velde CJ, de Haes HC
*(2009) Cancer Research **69** (2): 277S*

TEAM trial and substudies confirm the efficacy and safety of exemestane in women with early hormone-sensitive breast cancer.
Jones S, Coombes RC, Schilder CTM, Voskuil DW, van Nes J, Hadji P, Bartlett J.
(2008) Highlights from 31st SABCS)

Clinical implications of CYP2D6 genotyping on tamoxifen treatment in breast cancer.
Dezentje VO, Nortier JWR, Guchelaar HJ, van de Velde CJH, Gelderblom H.
*(2008) Ejc Supplements **6** (7): 56*

Endometrial safety of cross-over treatment with tamoxifen followed by exemestane.
Kieback DG, Harbeck N, Bauer W, Hadji P, Weyers G, Hasenburg A
*(2008) Ejc Supplements **6** (7): 198*

The effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: preliminary results of N-SAS (national surgical adjuvant study) BC04, the TEAM Japan sub-study.
Ihara T, Hozumi Y, Suemasu K, Takei H, Takehara M, Osumi S, Saito T, Masuda N, Ohashi Y
*(2007) Breast Cancer Research and Treatment **106** S114*

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: Report of a tamoxifen exemestane adjuvant Multicenter trial substudy.
Jones SE, Cantrell J, Vukelja S, Pippen J, O'Shaughnessy J, Blum JL, Brooks R, Hartung NL, Negron AG, Richards DA, Rivera R, Holmes FA, Chittoor S, Whittaker TL, Bordelon JH, Ketchel SJ, Davis JC,

Ilegbodu D, Kochis J, Asmar L
*(2007) Journal of Clinical Oncology **25** (30): 4765-4771*

The effect of exemestane, anastrozole and tamoxifen on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of NSAS (national surgical adjuvant study) BC04, the TEAM Japan sub-study.
Hozumi Y, Suemasu K, Takehara M, Takei H, Aihara T, Tamura M, Ohsumi S, Masuda N, Saito T, Mukai H, Ohashi Y
*(2006) Breast Cancer Research and Treatment **100** S188*

The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: Preliminary results of the TEAM Greek sub-study.
Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H
*(2005) Breast Cancer Research and Treatment **93** (1): 61-66*

The effect of exemestane on the lipidemic profile of breast cancer patients: Preliminary results of the TEAM trial Greek sub-study.
Markopoulos C, Polychronis A, Farfarelos C, Zobolas V, Papadiamantis J, Bafaloukos D, Misitzis J, Michailidou A, Gogas H
*(2004) Journal of Clinical Oncology **22** (14): 76S*

The effect of exemestane (Aromasin (R)) on the lipidemic profile of breast cancer patients: preliminary results of the TEAM trial Greek sub-study.
Markopoulos C, Polychronis A, Farfarelos C, Zobolas V, Bafaloukos D, Papadiamantis J, Misitzis J
*(2003) Breast Cancer Research and Treatment **82** S105*

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.
Engels CC, Charehbili A, van de Velde CJH, Bastiaannet E, Sajet A, Putter H, van Vliet EA, van Vlierberghe RL, Smit VT, Bartlett JM, Seynaeve C, Liefers GJ, Kuppen PJ.
Breast Cancer Res Treat. 2015 Feb;149(3):587-96.

Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial.
Fontein DB, Klinten Grand M, Nortier JW, Seynaeve C, Meershoek-Klein Kranenbarg E, Dirix LY, van de Velde CJH, Putter H.
Ann Oncol. 2015 Jun;26(6):1254-62.

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimann B, Seynaeve C, Putter H, van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW; Translational Aromatase Inhibitor Overview Group (Trans-AIOG).
Eur J Cancer. 2017 Jul;79:129-138

Adjuvant tamoxifen and exemestane in postmenopausal early breast cancer: ten-year analysis of the TEAM trial.

Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Meershoek-Klein Kranenbarg E, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Smeets J, Dirix LY, Paridaens R, van de Velde CJH.
Lancet Oncology. 2017, Jul 18 on-line

BOOG 2001-02 / AMAROS

The value of ultrasound in patients with T1-T2 breast cancer with no palpable lymph nodes enrolled in the EORTC 10981-22023 AMAROS trial
T.I.M. Snellen Netherlands
SGBCC poster 2025-P096

10-year follow-up of AMAROS shows benefits for post-operative radiotherapy to the axilla in patients with a tumour-positive sentinel node
EJT Rutgers et al,
SABCS 2018 oral presentation

Okselklierdissectie versus okselbestraling bij borstkankerpatiënten met een positieve schildwachtklier (de EORTC 10981 AMAROS-Studie).
M, Slaets L, Van Tienhoven G, Rutgers EJT.
Ned Tijdschr Geneeskd 2015; 159:1-7.

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3non-inferiority trial.
Donker M, Van Tienhoven G, E Straver M, Meijnen P, Van De Velde CJH, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JHG, Orzalesi L, Bouma WH, Van Der Mijle HCJ, Nieuwenhuijzen GAP, Veltkamp SC, Slaets L, DUEZ, NJ NJ, De Graaf PW, Van Dalen T, Marinelli AW, Rijna H, Snoj M, Bundred NJ, Merkus JWS, Belkacemi Y, Petignat P, Schinagl DAX, Coens C, Messina CGM, Bogaerts J, Rutgers EJT.
Lancet Oncol 2014; 15 (12):1303-1310.

Axillary lymph node dissection versus axillary radiotherapy: A detailed analysis of morbidity. Results from the EORTC 10981–22023 AMAROS trial.
Donker M, Rutgers EJT, Van De Velde CJH, Mansel RE, Westenberg AH, Orzalesi L, Slaets L, Bogaerts J, Van Tienhoven G.
Eur J Cancer 2013; 49 (supp 3):S14. 2013

Baseline results of the EORTC 10041/MINDACT TRIAL (Microarray In Node 0-3 positive Disease may Avoid ChemoTherapy).
Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Van'T Veer LJ, Rubio IT, Viale G, Nitz U, Pierga JY, Vindevoghel A, Brain E, Ravdin PM, Messina C, Cardoso F.
Poster presentation at the ECCO-ESMO-ESTRO Meeting, Amsterdam, NL, 27/09 - 01/10, 2013. Eur J Cancer; 49 (supp 2):S464.

Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: identification rate and nodal outcome.
Donker M, Straver ME, van Tienhoven G, van de Velde CJ, Mansel RE, Litière S, Werutsky G, Duez NJ, Orzalesi L, Bouma WH, van der Mijle H, Nieuwenhuijzen GA, Veltkamp SC, Helen Westenberg

A, Rutgers EJ.
Eur J Cancer. 2013 Jun;49(9):2093-100.

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023)
E. J. Rutgers, M. Donker, M. E. Straver, Ph. Meijnen, C. J. H. van de Velde, R. E. Mansel, H. Westenberg, L. Orzalesi, W.H. Bouma, H. van der Mijle, G. A. P. Nieuwenhuijzen, S. C. Veltkamp, L. Slaets, C.G. M. Messina, N. J. Duez, C. Hurkmans, J. Bogaerts, and G. van Tienhoven
Oral Presentation at the ASCO Meeting. Chicago, USA, 31/05 - 4/06, 2013. J Clin Oncol; 31 (18)

Sentinel Node Identification Rate and Further Nodal Involvement in Patients with Multifocal Breast Cancer in the EORTC 10981-22023 AMAROS Trial.
Donker M, Straver ME, Meijnen P, Van Tienhoven G, Van De Velde CJH, Litière S, Werutsky G, Duez N, Rutgers EJT.
Eur J Cancer 2012.

Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.
Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Duez N, Cataliotti L, Klinkenbijl JH, Westenberg HA, van der Mijle H, Snoj M, Hurkmans C, Rutgers EJ.
Ann Surg Oncol. 2010 Jul;17(7):1854-61.

Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer.
Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Demonty G, Duez N, Cataliotti L, Klinkenbijl J, Westenberg HA, van der Mijle H, Hurkmans C, Rutgers EJ.
J Clin Oncol. 2010 Feb 10;28(5):731-7.

Technical aspects of the sentinel node biopsy in the EORTC AMAROS sentinel node trial.
Straver ME, Meijnen P, Van Tienhoven G, Van De Velde CJ, Mansel RE, Bogaerts J, Demonty G, Rutgers EJ. *2008.*

Patterns of care in the EORTC AMAROS sentinel node trial.
Straver ME, Meijnen P, Tienhoven G, Van De Velde CJ, Mansel RE, Bogaerts J, Demonty G, Duez N, Rutgers EJ
2008.

Analyses met betrekking tot de technische aspecten, gebaseerd op de eerste 2000 patiënten zijn (met toestemming van de IDMC)
ASCO Breast Cancer Symposium (Washington DC, september 2008) en 31st San Antonio Breast Cancer Symposium in december 2008.

European Organisation for Research and Treatment of Cancer (EORTC) 10981-22023 after mapping of the axilla radiotherapy or surgery (AMAROS) trial update.
Meijnen P, Distante V, Van De Velde CJH, Van Tienhoven G, Duez N, Bogaerts J, Rutgers EJT.
Eur J Cancer 2006.

Amaros trial: after mapping of the axilla radiotherapy or surgery? Current status.
Meijnen P, Distante V, Van De Velde CJH, Van Tienhoven G, Duez N, Bogaerts J, Rutgers EJT.
EORTC 10981-22023

Eur J Cancer 2005.

EORTC 10981-22023 AMAROS trial: After mapping of the axilla: Radiotherapy or surgery? Current Status.
Meijnen P, Distante V, Van De Velde CJH, Van Tienhoven G, Duez N, Bogaerts J, Rutgers
EJTH 2005.

AMAROS: After mapping of the axilla: Radiotherapy or surgery? Trial update.
Meijnen P, Rutgers EJT, Van De Velde CJH, Van Tienhoven G, Distante V, Duez N. EORTC 10981-22023 trial.
Eur J Cancer 2004.

Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run.
Hurkmans CW, Borger JH, Rutgers EJ, van Tienhoven G; EORTC Breast Cancer Cooperative Group; Radiotherapy Cooperative Group.
Radiother Oncol. 2003 Sep;68(3):233-40.

BOOG 2002-02 / HERTAX

Randomized phase II study comparing efficacy and safety of combination therapy trastuzumab and docetaxel versus sequential therapy of trastuzumab followed by docetaxel alone at progression as first line chemotherapy in patients with HER2-positive metastatic breast cancer: HERTAX trial.
P. Hamberg, M. M.E.M. Bos, H.J.J. Braun, J.M.L. Stouthard, G. A. van Deijk, F. L.G. Erdkamp, I.N. van der Stelt-Frissen, M. Bontenbal, G.J. M. Creemers, J.E.A. Portielje, J.F.M. Pruijt, O.J.L. Loosveld, W.M. Smit, E.W. Muller, P. I.M. Schmitz, C.Seynaeve, J.G.M. Klijn
Clinical Breast Cancer April 2011 p 103-113

Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study).
M. Bontenbal, C. Seynaeve, J. Stouthard, M. Bos, H. Braun, F. Erdkamp, G. van Deijk, P. Schmitz, I. van der Stelt-Frissen, P. Hamberg, J. Klijn
J Clin Oncol 26: 2008 (May 20 suppl; abstr 1014) Oral presentation

Sequential Rx effective, less toxic in metastatic breast cancer;
Oncology News International feb'08

Combined trastuzumab (HER)/docetaxel (TAX) versus sequential trastuzumab followed by docetaxel at progression as first line chemotherapy for Her2-positive metastatic breast cancer: preliminary results (HERTAX).
P Hamberg, JML Stouthard, MM Bos, HJ Braun, F Erdkamp, G van Deijk, M Bontenbal, RM Vernhout, PIM Schmitz, C Seynaeve, JGM Klijn
Breast Cancer Research and Treatment, Vol. 106, Supplement 1, 2007; Abstract 1077

BOOG 2002-04 / HERA

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators
Clin Cancer Res. 2018 Jul 1;24(13):3079-3086.

Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J;
Lancet 382:1021-1028, 2013. (IBCSG 28-02) (Journal impact factor 39.060).

Three HERA abstracts were presented at SABCS 2011 (manuscripts under review):
1. Trastuzumab does not increase the incidence of central nervous system (CNS) relapses in HER2 positive early breast cancer: the HERA trial experience
2. Pregnancy during and following adjuvant trastuzumab in patients with HER2-positive breast cancer: An analysis from the HERA trial
3. The magnitude of trastuzumab benefit in HER2-positive (HER2+) lobular breast carcinoma (BC): Results from the HERA Trial
One publication:
Pregnancy during and following adjuvant trastuzumab in patients with HER2-positive breast
cancer: An analysis from the HERA trial (BIG 1-01), *Breast Cancer Res Treat*

Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.
Younis T, Skedgel C.
Pharmacoeconomics. 2011 May 1;29(5):361-5. doi: 10.2165/11588350-000000000-00000. No abstract available.

HERA crosses over.
Joensuu H. *Lancet Oncol. 2011 Mar;12(3):203-4. Epub 2011 Feb 25. No abstract available.*

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team.
Lancet Oncol. 2011 Mar;12(3):236-44. Epub 2011 Feb 25.

The Effect of Age on Breast Cancer Outcomes in Women with Her-2 Positive Breast Cancer: Results from the HERA Trial
Partridge AH, Gelber S, Piccart M, Focant F, Scullion M, Winer E, Gelber R, on Behalf of the HERA Trial Study Team.
Cancer Res; 70(24 Suppl) Dec 15, 2010; P4-09-12

Impact of HER2 Staining Intensity on Prognosis and Treatment Benefit of Adjuvant Trastuzumab Given after Chemotherapy: the HERA Trial Experience
Zabaglo L, Stoss O, Rueschoff J, Zielinski D, Salter J, Bradbury I, Arfi M, Dafni O, Procter M, Dowsett M, HERA Trial Study Team
Cancer Res; 70(24 Suppl) Dec 15, 2010; PG10-01

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ.
J Clin Oncol. 2010 Jul 20;28(21):3422-8. Epub 2010 Jun 7.

The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.
Skedgel C, Rayson D, Younis T.
Value Health. 2009 Jul-Aug;12(5):641-8.

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B.
J Clin Oncol. 2009 Jun 20;27(18):2962-9. Epub 2009 Apr 13.

When an interim analysis of randomized trial changes the practice in oncology: the lesson of adjuvant Trastuzumab and the HERA trial.
De Rossi C, Brunello A, Jirillo G, Jirillo A.
Immunopharmacol Immunotoxicol. 2009 Mar;31(1):30-1. Review.

When an interim analysis of randomized trial changes the practice in oncology: The lesson of adjuvant trastuzumab and the HERA trial.
De Rossi C, Brunello A, Jirillo G, Jirillo A.
Immunopharmacol Immunotoxicol. 2009;31(1):1-4.

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A; HERA Study Team.
Ann Oncol. 2008 ;18:909-916.

Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial.
Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D.
Ann Oncol. 2007 Sep;18(9):1493-9.

The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.
Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K.

Breast Cancer Res Treat. 2008 Jun;109(3):559-66. Epub 2007 Jul 28.

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ.
J Clin Oncol. 2007 Sep 1;25(25):3859-65. Epub 2007 Jul 23.

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith, Marion Procter, Richard D Gelber, Sébastien Guillaume, Andrea Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, Jose Baselga, Manfred Kaufmann, David Cameron, Richard Bell, Jonas Bergh, Robert Coleman, Andrew Wardley, Nadia Harbeck, Roberto I Lopez, Peter Mallmann, Karen Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez Rovira, Martine J Piccart-Gebhart, for the HERA study team *The Lancet, Vol 369 (9555):29-36, January 6, 2007*

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.
NEJM 2005; 353:1659- 1672.

BOOG 2003-02 / CALOR

The Final Verdict: Chemotherapy Benefits Estrogen Receptor-Negative Isolated Local Recurrence.
Chan N, Toppmeyer DL.
J Clin Oncol. 2018 Apr 10, doi: 10.1200/JCO.2017.77.4877.

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
Wapnir IL, Price KN, Anderson SJ, Robidoux A, Martín M, Nortier JWR, Paterson AHG, Rimawi MF, Láng I, Baena-Cañada JM, Thürlimann B, Mamounas EP, Geyer CE Jr, Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S;
J Clin Oncol. 2018 Feb 14 doi: 10.1200/JCO.2017.76.5719.

Chemotherapy (CT) for Isolated Locoregional Recurrence (ILRR) of Breast Cancer in ER-Positive (ER+) and ER-Negative (ER-) Cohorts: Final Analysis of the CALOR Trial International Breast Cancer Study Group, Breast International Group, NRG Oncology (NSABP Legacy)
Irene Wapnir, Karen N. Price, Stewart J. Anderson, Andre Robidoux, Miguel Martín, J. W. R. Nortier, Alexander H. G. Paterson, Mothaffar F. Rimawi,
István Láng, José Manuel Baena Cañada, Beat J. K. Thürlimann, Eleftherios P. Mamounas, Charles E. Geyer Jr., Shari Gelber, Alan S. Coates,
Richard D. Gelber, Priya Rastogi, Meredith M. Regan, Norman Wolmark, Stefan Aebi

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial
Irene L. Wapnir, MD1, Shari Gelber, MS2, Stewart J. Anderson, PhD3, Eleftherios P. Mamounas, MD4,
Andre´ Robidoux, MD5, Miguel Martı´n, MD6, Johan W. R. Nortier, MD7, Charles E. Geyer Jr, MD8,

Alexander H. G. Paterson, MD9, Istva´n La´ng, MD10, Karen N. Price, BS2, Alan S. Coates, MD11, Richard D. Gelber, PhD12, Priya Rastogi, MD13, Meredith M. Regan, ScD14, Norman Wolmark, MD15, Stefan Aebi, MD16, and On behalf of CALOR trial investigators.
Annuals of Surgical Oncology – 2017

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
Dr Stefan Aebi, Shari Gelber , Stewart J Anderson, István Láng , André Robidoux , Miguel Martín , Johan W R Nortier , Alexander H G Paterson ,, Mothaffar F Rimawi ,, José Manuel Baena Cañada ,, Beat Thürlimann MD c o, Elizabeth Murray MD p, Eleftherios P Mamounas MD q, Charles E Geyer MD r, Karen N Price ,, Alan S Coates , t, Richard D Gelber ,, Priya Rastogi ,, Norman Wolmark ,, Irene L Wapnir
The Lancet Oncology, Volume 15, Issue 2, Pages 156 - 163, February 2014

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer; IBCSG 27-02, NSABP B-37, BIG 1-02)
Aebi S, Gelber S, Láng I, Anderson SJ, Robidoux A, Martín M, Nortier JWR, Mamounas EP, Geyer, Jr. CE, Maibach R, Gelber RD, Wolmark N, Wapnir IL. International Breast Cancer Study Group, Bern, Switzerland; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Breast International Group, Brussels, Belgium
SABCS 2012

Patterns of locoregional failure in the CALOR (Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer) Trial IBCSG 27–02, NSABP B–37, BIG 1–02
Irene L. Wapnir, Shari Gelber, István Láng, Stewart J. Anderson, André Robidoux, Miguel Martín, Johan W.R. Nortier, Eleftherios P. Mamounas, Charles E. Geyer, Jr., Rudolf Maibach, Richard D. Gelber, Norman Wolmark, Stefan Aebi
Accepted SABCS 2012

Progress on BIG 1-02/IBCSG 27-02/ NSABP B-37, A Prospective Randomized Trial of Evaluating Chemotherapy after Local Therapy for Isolated Locoregional Recurrences of Breast Cancer
Irene L. Wapnir, Stefan Aebi, Shari Gelber, Charles E. Geyer, Stewart Anderson, István Láng, Andre Robidoux A, Mamounas EP, Wolmark N
Ann Surg Oncol 15:3227-3231, 2008

A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.
Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, Robidoux A, Bernhard J, Maibach R, Castiglione-Gertsch M, Coates AS, Piccart MJ, Clemons MJ, Costantino JP, Wolmark N.
Clinical Breast Cancer 8:287-292, 2008.

BOOG 2003-04 / BCP

Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study.
Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B, Loibl S.

J Clin Oncol. 2013; 10;31:2532-9

Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial
Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring A, Giermek J, Fehm T, Wildiers H, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Lenhard M, Witteveen PO, Kaufmann M, Van Calster B, Loibl S
Cancer Res; 72(24 Suppl) Dec 15, 2012; 514 s (P6-07-05)

Treatment of breast cancer during pregnancy: an observational study.
S. Loibl, S. N. Han, G. Von Minckwitz, M. Bontenbal, A. Ring, J. Giermek, T. Fehm, K. Vanalsteren, S. Linn, B. Schlehe, et al.
The Lancet Oncology. 2012 Sept; 13(9): pag 887-896

Patients with Breast Cancer during Pregnancy – Results from a Prospective and Retrospective Registry (GBG-20/BIG02-03).
Loibl S, Amant F, Kaufmann M, Ring A, Sileny H, Giermek J, Fehm T, Bontenbal M, Heinrigs M, Lenhard M, Scherr I, Mehta K, von Minckwitz G.
Cancer Res; 70(24 Suppl) Dec 15, 2010; S6-2

Breast cancer in pregnancy: recommendations of an international consensus meeting.
Amant F, Deckers S, Van Calsteren K, Loibl S, Halaska M, Brepoels L, Beijnen J, Cardoso F, Gentilini O, Lagae L, Mir O, Neven P, Ottevanger N, Pans S, Peccatori F, Rouzier R, Senn HJ, Struikmans H, Christiaens MR, Cameron D, Du Bois A.
Eur J Cancer. 2010 Dec;46(18):3158-68.

Breast cancer during pregnancy – a prospective and retrospective European registry (GBG-20/BIG02-03)
Loibl S, Bontenbal M, Ring A, UFK FFM NN, Crivellari D, Fehm T, Heinrigs M, Lenhard M, Mehta K, von Minckwitz G
Abstract EBCC 2010

BOOG 2004-01 / Young Boost (CKTO 2003-13)

A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients
Sophie C.J.Bosma, MarlousHoogstraat, Erikvan Werkhoven, Michiel de Maaker, Femke van der Leij, Paula H.M.Elkhuizen, AlainFourquet, PhilipPoortmanseh, Liesbeth J.Boersma, HarryBartelink, Marc J.van de Vijver, Young Boost Trial research group
Radiother Oncol. March 2021 Volume 156, March 2021, Pages 127-135, doi.org/10.1016/j.radonc.2020.11.025

Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial.
Brouwers PJAM, van Werkhoven E, Bartelink H, Fourquet A, Lemanski C, van Loon J, Maduro JH, Russell NS, Scheijmans LJEE, Schinagl DAX, Westenberg AH, Poortmans P, Boersma LJ; Young Boost Trial research group.
Radiother Oncol. 2018 Sep;128(3):434-441. doi: 10.1016/j.radonc.2018.06.020. Epub 2018 Jul 3.

Factors associated with patient-reported cosmetic outcome in the Young Boost Breast Trial.
Brouwers PJ, van Werkhoven E, Bartelink H, Fourquet A, Lemanski C, van Loon J, Maduro JH, Russell NS, Scheijmans LJ, Schinagl DA, Westenberg AH, Poortmans P, Boersma LJ; Young Boost Trial research group.
Radiother Oncol. 2016 Jul;120(1):107-13. doi: 10.1016/j.radonc.2016.04.017. Epub 2016 May 28.

The influence of the boost dose on cosmetic outcome after breast conserving therapy: results of the Young Boost Trial
P.J.A.M. Brouwers[a], E van Werkhoven[b], B. Hanbeukers[a], J. van Loon[a], J.W. Leer[c], P.M. Poortmans[c], H.Bartelink[b] and L.J. Boersma[a] on behalf of the Young Boost Trial research group.
ESTRO 2015, Barcelona.

Phase III trial of low vs high radiation boost in young breast cancer patients
Boersma L., Bartelink H., Poortmans P.M., Leer J.W.
V&VN-oncologica nummer 01.2011

Multi-institutional study on target volume delineation variation in breast radiotherapy in the presence of guidelines.
van Mourik AM, Elkhuizen PH, Minkema D, Duppen JC; Dutch Young Boost Study Group, van Vliet-Vroegindeweij C**.**
Radiother Oncol. 2010 Mar;94(3):286-91. Epub 2010 Mar 2.

The influence of the use of CT-planning on the irradiated boost volume in breast conserving treatment.
Al Uwini S, Antonini N, Poortmans PM, Boersma L, Hurkmans C, Leer JW, Horiot JC, Struikmans H, Bartelink H.
Radiother Oncol. 2009 Oct;93(1):87-93. Epub 2009 Jun 8.

BOOG 2004-02 / TBP

Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.
von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; On behalf of the GBG 26/BIG 03-05 study group and participating investigators.
Eur J Cancer. 2011 Jul 7

Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment.
von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh F, Baumann K, Bischoff J, Harbeck N, Lück H-J, Maass N, Zielinski C, Andersson M, Stein R, Nekljudova V, Loibl S.
Cancer Res; 70(24 Suppl) Dec 15, 2010;P6-14-05

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

Gunter von Minckwitz, Andreas du Bois, Marcus Schmidt, Nicolai Maass, Tanja Cufer, Felix E. de Jongh, Eduard Maartense, Christoph Zielinski, Manfred Kaufmann, Wolfgang Bauer, Klaus H. Baumann, Michael R. Clemens, Ralph Duerr, Christoph Uleer, Michael Andersson, Robert C. Stein, Valentina Nekljudova, and Sibylle Loibl
JCO Vol 27, Nr 12, April 20, 2009

Continuing Trastuzumab Beyond Progression
Jahanzeb M, Division of Hematology Oncology, College of Medicine, University of Tennessee, Memphis, TN, and Aptium Oncology, Lynn Cancer Institute, West Campus, Boca Raton, FL
JCO Vol 27, Nr 12, April 20, 2009

Media Release: Trastuzumab improves the efficacy of chemotherapy in breast cancer treatment beyond progression (results of a multicenter, randomized phase III study comparing capecitabine alone versus in combination with trastuzumab in patients with HER2-positive metastatic breast cancer and progression after previous treatment with trastuzumab)
German Breast Group, September 14, 2008

Continuering van combinatietherapie bij behandeling van uitgezaaide borstkanker remt ziekteprogressie
Persbericht 9 juni 2008

Capecitabine vs. capecitabine + trastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment – the TBP phase III study (GBG 26 / BIG 3-05)
Von Minckwitz G, Zielinski C, Maartense E, du Bois A, Schmidt M, Maass N, Cufer T, De Jongh FE, Andersson M, Stein R, Kaufmann M, Nekljudova V, Loibl S
Presented at the 44th ASCO Annual Meeting 2008, May 30-June 3, Chicago, Illinois , USA

Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer –the TBP study (GBG 26/BIG 3-05).
Von Minckwitz G, Vogel P, Schmidt M, Eidtmann H, Cufer T, de Jongh F, Maartense E, Zielinski C, Andersson M, Stein R, Nekljudova V, Loibl S
Breast Cancer Research and Treatment, Vol. 106, Supplement 1, 2007; ASCO Abstract 4056

BOOG 2004-04 / MATADOR

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity
Stefan Prekovic #, Theofilos Chalkiadakis #, Merel Roest #, Daniel Roden, Catrin Lutz, Karianne Schuurman, Mark Opdam, Liesbeth Hoekman, Nina Abbott, Tanja Tesselaar, Maliha Wajahat, Amy R Dwyer, Isabel Mayayo-Peralta, Gabriela Gomez, Maarten Altelaar, Roderick Beijersbergen, Balázs Győrffy, Leonie Young, Sabine Linn, Jos Jonkers, Wayne Tilley, Theresa Hickey, Damir Vareslija, Alexander Swarbrick, Wilbert Zwart
EMBO Mol Med. 2023

Differential Survival and Therapy Benefit of Patients with 4 Breast Cancer Are Characterized By Distinct Epithelial and Immune Cell Microenvironments
Lennart Kester, Danielle Seinstra, Annelot G.J. van Rossum, Claire Vennin, Marlous Hoogstraat, Daphne van der Velden, Mark Opdam, Erik van Werkhoven, Kerstin Hahn, Iris Nederlof, Ester H. Lips, Ingrid A.M. Mandjes, A.Elise van Leeuwen-Stok, Sander Canisius, Harm van Tinteren, Alex L.T. Imholz, Johanneke E.A. Portielje, Monique E.M.M. Bos, Sandra D. Bakker, Emiel J. Rutgers,

Hugo M. Horlings, Jelle Wesseling, Emile E. Voest, Lodewyk F.A. Wessels, Marleen Kok, Hendrika M. Oosterkamp, Alexander van Oudenaarden, Sabine C. Linn, and Jacco van Rheenen
Clin Cancer Res 2022

FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer
Sandra Tavares, Nalan Liv, Milena Pasolli, Mark Opdam, Max A K Rätze, Manuel Saornil, Lilian M Sluimer, Rutger C C Hengeveld, Robert van Es, Erik van Werkhoven, Harmjan Vos, Holger Rehmann, Boudewijn M T Burgering, Hendrika M Oosterkamp, Susanne M A Lens, Judith Klumperman, Sabine C Linn, Patrick W B Derksen
Cell Rep. 2022

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.
Mark Opdam, Annelot G.J. van Rossum, Marlous Hoogstraat, Gergana Bounova, Hugo M. Horlings, Erik van Werkhoven, Ingrid A.M. Mandjes, A. Elise van Leeuwen – Stok, Sander Canisius, Harm van Tinteren, Alex L.T. Imholz, Johanneke E.A. Portielje, Monique E.M.M. Bos, Sandra Bakker, Jelle Wesseling, Lennart Kester, Jacco van Rheenen, Emiel J. Rutgers, Renee X. de Menezes, Lodewyk F.A. Wessels, Marleen Kok, Hendrika M. Oosterkamp, Sabine C. Linn, the MATADOR trialists' group for the Dutch Breast Cancer Research Group (BOOG).
iScience. 2024 Aug 16

MATADOR: A prospective, randomised, phase III biomarker trial in breast cancer patients.
Mark Opdam, Annelot van Rossum, Renee Menezes, Marleen Kok, Rianne Oosterkamp, Sabine Linn. *Mendeley Data. 2024; V2*

MATADOR Trialists' Group. Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).
van Rossum AGJ, Kok M, van Werkhoven E, Opdam M, Mandjes IAM, van Leeuwen-Stok AE, van Tinteren H, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, Wesseling J, Rutgers EJ, Linn SC, Oosterkamp HM**.**
Eur J Cancer, 2018:102:40-48

Multi-centric validation of an AI-based sTIL% scoring model for breast cancer H&E whole-slide images
Yoni Schirris, Rosie A. B. Voorthuis, Mark Opdam, Efstratios Gavves, UvA, Renee X. Menezes, Sabine C. Linn, Hugo Mark Horlings
Abstract ESMO 2023

Tumor infiltrating lymphocytes predict benefit from TAC but not from ddAC in triple negative breast cancer in the randomized MATADOR trial (BOOG 2004-04)
A.G.J. van Rossum, M. Hoogstraat, M. Opdam, H. Horlings, L. Wessels, R.M. Kerkhoven, A.E. van Leeuwen - Stok, H.M. Oosterkamp, M. Kok, S.C. Linn*Abstract ESMO 2018*

Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.
van Rossum AGJ, Kok M, McCool D, Opdam M, Miltenburg NC, Mandjes IAM, van Leeuwen-Stok E, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, van Werkhoven E, Schmidt MK, Oosterkamp HM, Linn SC.

Oncotarget, 8:113531-113542, 2017.

Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: first results of the randomized MATADOR trial (BOOG-2004-04)
A.G.J. van Rossum, H.M. Oosterkamp, E. van Werkhoven, M. Opdam, I.A.M. Mandjes, A.E. van Leeuwen – Stok, H. van Tinteren, M. Kok, A.L.T. Imholz, J.E.A. Portielje, M.M.E.M. Bos, A. van Bochove, J. Wesseling, E.J. Rutgers, S. Rodenhuis, S.C. Linn; (on behalf of the) Dutch Breast Cancer Research Group.
Abstract SABCS 2016

GSTP1 polymorphism is associated with chemotherapy-induced neuropathy
N.C.Miltenburg, M.Opdam, M.Winter, M.van Geer, H.M.Oosterkamp, W.Boogerd en S.C.Linn
SABCS 2012

De MATADOR-studie: multicenter fase-III-onderzoek naar chemotherapie op maat bij het mammacarcinoom.
Linn SC, Helgason HH, Oosterkamp HM
Ned Tijdschr Oncol 2005;2:193-8.

BOOG 2005-03 / MINDACT

Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial.
Lopes Cardozo JMN, Byng D, Drukker CA, *et* al.
Annals of Oncology; Published online 30 November 2021.
(*https://doi.org/10.1016/j.annonc.2021.11.014*).

Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer.
Lopes Cardozo JMN, Schmidt MK, van 't Veer LJ, Cardoso F, Poncet C, Rutgers EJT, Drukker CA. *Br Cancer Research and Treatment, June 2021 (https://doi.org/10.1007/s10549-021-06315-3).*

Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial.
Josephine Lopes Cardozo, Caroline Drukker, Marjanka Schmidt, Laura van 't Veer, Annuska Glas, Anke Witteveen, Fatima Cardoso, Martine Piccart, Coralie Poncet, Emiel Rutgers.
Oral presentation at the ASCO Annual Meeting, June 2021; DOI: 10.1200/JCO.2021.39.15_suppl.500 Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 500-500.

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the Phase 3 randomized MINDACT trial with an exploratory analysis by age.
M Piccart, LJ van 't Veer, C. Poncet, JMN Lopes Cardozo, S Delaloge, JY Pierga, P Vuylsteke, E Brain, S Vrijaldenhoven, PA Neijenhuis, S Causeret, TJ Smilde, G Viale, AM Glas, M Delorenzi, C Sotiriou, IT Rubio, S Kümmel, G Zoppoli, AM Thompson, E Matos, K Zaman, F Hilbers, D Fumagalli, P Ravdin, S Knox, K Tryfonidis, A Perić, B. Meulemans, J Bogaerts, F Cardoso, EJTh Rutgers, on behalf of all MINDACT investigators.
Published in The Lancet Oncology, March 2021 (https://doi.org/10.1016/S1470-2045(21)00007-3).

Edito: **Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.**
Piccart MJ, Kalinsky K, Gray R, Barlow WE, Poncet C, Cardoso F, Winer E, Sparano J.

Ann Oncol. 2021 Sep;32(9):1077-1082

Geactualiseerde resultaten van de klinische studie MINDACT
F. Cardoso
BIG against breast cancer 05-06-2020

How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status
Laura J van 't Veer et al,
SABCS 2020 PS6-01

Outcome without adjuvant systemic treatment in breast cancer patients included in the MINDACT trial
JMN Lopes Cardozo et al,
SABCS 2020 PS11-01

Clinical Utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial.
Metzger O, Cardoso F, Poncet C et al.
EBCC-12 ORAL-007, plenary session

Updated results of the MINDACT trial: 70-gene signature to guide de-escalation of chemotherapy in early breast cancer.
Rutgers E J T,
EBCC-12, ORAL-021, proffered papers session

Screen-detected breast cancers have different tumour biology and better prognosis compared to interval breast cancers.
Lopes Cardozo J,
EBCC-12, ORAL-011, proffered papers session

Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
Delaloge S, Piccart M, Rutgers E, Litiere S, Van'T Veer L, van den Berkmortel F, Brain E, Dudek-Peric A, Gil-Gil M, Gomez P, Hilbers F, Khalil Z, Knox S, Kuemmel S, Kunz G, Lesur A, Pierga JY, Ravdin P, Rubio I, Saghatchian M, Smilde T, Thompson A, Viale G, Zoppoli G, Vuylsteke P, Tryfonidis K, Poncet C, Bogaerts J, Cardoso F, MINDACT Investigators and the TRANSBIG Consortium.
J Clin Oncol 2020.

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
Viale G, De Snoo F, Slaets L, Bogaerts J, Van't Veer L, Rutgers E, Piccart M, Stork-Sloots L, Glas A, Russo L, Dell'Orto P, Tryfonidis K, Litiere S, Cardoso F.
Breast Cancer Res Treat 2018; 167 (1):122-131.2018

Not all small node negative (pT1abN0) breast cancers are similar: Outcome results from the EORTC 10041/BIG 3-04 (MINDACT) trial.

Tryfonidis K, Poncet C, Slaets L, Viale G, Snoo F, Aalders A, Van 't Veer L, Rutgers E, Piccart M, Bogaerts J, Cardoso F.
Oral Presentation at the ESMO Annual Meeting, Madrid, Spain, September 7 – 12, 2017. Ann Oncol; 28 (Suppl 5):v605-649. 2017

Delaloge S. Standard anthracycline-based vs. Docetaxel-Capecitabine in early breast cancer: results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial.
F, Piccart-Gebhart MJ, Rutgers E, Litiere S, van't Veer L, Viale G, Pierga JY, van den Berkmortel F, Brain E, Gomez P, Goulioti T, Knox S, Luporsi E, Nitz U, Rubio I, Stork L, Vuylsteke P, Tryfonidis K, Bogaerts J, *Poster Presentation at the ASCO Annual Meeting, Chicago, Illinois, United States, June 2-6, 2017. J Clin Oncol; 35. 2017*

Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
Aalders KC, Kuijer A, Straver ME, Slaets L, Litiere S, Viale G, Vant Veer LJ, Glas AM, Delorenzi M, van Dalen T, Tryfonidis K, Piccart-Gebhart M, Cardoso F, Rutgers EJ
Eur J Cancer. 2017; 79:98-105 Jul doi: 10.1016/j.ejca.2017.03.034. Epub 2017 May 3.

High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Viale G, Slaets L, Bogaerts J, Rutgers E, van't Veer L, Piccart-Gebhart MJ, de Snoo FA, Stork-Sloots L, Russo L, Dell'Orto P, van den Akker J, Glas A, Cardoso F; TRANSBIG Consortium & the MINDACT Investigators.
Ann Oncol. 2014 Apr;25(4):816-23. doi: 10.1093/annonc/mdu026.

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F.
Eur J Cancer. 2011 Dec;47(18):2742-9. doi: 10.1016/j.ejca.2011.09.016. Epub 2011 Nov 1.

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. Mook S, Bonnefoi H, Pruneri G, Larsimont D, Jaskiewicz J, Sabadell MD, Macgrogan G, Van't Veer LJ, Cardoso F, Rutgers EJ.
Eur J Cancer. 2009 May;45(7):1201-8. doi: 10.1016/j.ejca.2009.01.004. Epub 2009 Feb 14.

Clinical application of the 70-gene profile: the MINDACT trial.
Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ.
J Clin Oncol. 2008 Feb 10;26(5):729-35. doi: 10.1200/JCO.2007.14.3222.

The MINDACT trial: the first prospective clinical validation of a genomic tool.
Cardoso F, Piccart-Gebhart M, Van't Veer L, Rutgers E; TRANSBIG Consortium.
Mol Oncol. 2007 Dec;1(3):246-51. doi: 10.1016/j.molonc.2007.10.004. Epub 2007 Oct 22.

Individualization of therapy using Mammaprint: from development to the MINDACT Trial.
Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F.
Cancer Genomics Proteomics. 2007 May-Jun;4(3):147-55. Review.

TRANSBIG consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.

Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M;
Nat Clin Pract Oncol. 2006 Oct;3(10):540-51. Review.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators.
N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, ThompsonAM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators.
N Engl J Med. 2016 Aug 25;375(8):717-29.

Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) vs clinical subtypes for breast cancer, among 6,694 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial
Giuseppe Viale1, Leen Slaets2, Femke A de Snoo3, Jan Bogaerts2, Laura J van 't Veer4, Emiel J Rutgers5, Martine J Piccart-Gebhart6, Jeroen van den Akker3, Lisette Stork-Sloots3, Leila Russo1, Patrizia Dell'Orto1, Fatima Cardoso7
SABCS 2014 publication number: P4-11-08

Are all small tumors low risk? Characterization of small invasive node negative breast cancers (BC) enrolled in the EORTC 10041/BIG 3-04 (MINDACT) trial
Konstantinos Tryfonidis1, Leen Slaets2, Giuseppe Viale3, Femke Snoo4, Laura Van't Veer5, Emiel Rutgers6, Martine Piccart7, Jan Bogaerts2 and Fatima Cardoso8.
SABCS 2014, publication number: P2-03-01

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.
Rutgers E1, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso **F.**
Eur J Cancer. 2011 Dec;47(18):2742-9.

The EORTC 10041/BIG 03-04 MINDACT (Microarray in Node Negative Disease may Avoid ChemoTherapy) Trial: Patients' baseline Characteristics and Logistics Aspects After a Successfull Accrual
Piccart M, Bogaerts J, Cardoso F, Werutsky G, Delaloge S, Van 't Veer L, Rubio I, Moulin C, Engelen K, Viale G, Thompson AM, Passalacqua, Nitz U, Vuylsteke P, Pierga JY, Rutgers E
Abstract ESMO 2011

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ; TRANSBIG Consortium.

Breast Cancer Res Treat. 2009 Jul;116(2):295-302.

Clinical application of the 70-gene profile: the MINDACT trial.
Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ.
J Clin Oncol. 2008 Feb 10;26(5):729-35

MINDACT Microarray in Node Negative Disease may Avoid ChemoTherapy. Een unieke studie voor borstkankerpatiënten en onderzoeker.
I. Eekhout, S. Mook, E.Th Rutgers
Nederlands Tijdschrift voor Oncologie, 2008

The MINDACT trial: the first prospective clinical validation of a genomic tool
Cardoso F, Piccart-Gebhart M, Van't Veer L, Rutgers E; TRANSBIG Consortium.
Mol Oncol. 2007 Dec;1(3):246-51.

Individualization of Therapy Using Mammaprint: from Development to the MINDACT trial
Stella Mook, Laura Van't Veer, Emiel Rutgers, Martine Piccart-Gebhart and Fatima Cardoso
CANCER GENOMICS & PROTEOMICS 4: 147-156 (2007)

MINDACT Trial: A prospective trial to validate the Amsterdam signature
Rutgers E.
Breast International Group 1 ASCO 43rd Annual meeting 2007 - Educational Book: 40-44,2007.

Individualization of therapy using Mammaprint: from development to the MINDACT Trial.
Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F.
Cancer Genomics Proteomics. 2007 May-Jun;4(3):147-55.

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M; TRANSBIG consortium.
Nat Clin Pract Oncol. 2006 Oct;3(10):540-51.

BOOG 2006-01 / DATA
The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial
Lammers SWM, Geurts SME, Hermans K, Kooreman LFS, Swinkels ACP, Smorenburg CH, et al.
ESMO Open. 2025;10(2):104154

The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer
Lammers SWM, Geurts SME, van Hellemond IEG, Swinkels ACP, Smorenburg CH, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, de Roos WK, Linn SC, Imholz ALT, Smidt ML, Vriens IJH, Tjan-Heijnen VCG.
JNCI Cancer Spectr. 2023 Oct 31;7(6):pkad092. doi: 10.1093/jncics/pkad092. PMID: 37991939; PMCID: PMC10697786.

Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial
Lammers SWM, Geurts SME, Hermans KEPE, van Hellemond IEG, Swinkels ACP, Smorenburg CH, van der Sangen MJC, Kroep JR, Honkoop AH, van den Berkmortel FWPJ, de Roos WK, Imholz

ALT, Vriens IJH, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG) for the DATA investigators.
Breast Cancer Res Treat. 2024 Jun 28. doi: 10.1007/s10549-024-07411-w. Epub ahead of print. PMID: 38940981.

Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial.
Tjan-Heijnen VCG, Lammers SWM, Geurts SME*, et al.*
eClinicalMedicine 2023;58:101901.
Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
Van Hellemond IEG, Smorenburg CH, Peer PGM, Swinkels ACP, Seynaeve CM, van der Sangen MJC, et al.
Breast Cancer Res Treat. 2020;180(3):675-85.

The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study.
De Ruijter TC, Smits KM, Aarts MJ, van Hellemond IEG, van Neste L, de Vries B, et al.
Diagn Progn Res. 2019;3:20.

Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.
Van Hellemond IEG, Smorenburg CH, Peer PGM, Swinkels ACP, Seynaeve CM, van der Sangen MJC, et al.
Int J Cancer. 2019;145(5):1325-33.

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.
Van Hellemond IEG, Vriens IJH, Peer PGM, Swinkels ACP, Smorenburg CH, Seynaeve CM, et al.
Int J Cancer. 2019;145(1):274-83.

No impact of osteoporosis or bisphosphonate use for osteoporosis on breast cancer outcome: A sub-study of the DATA trial
I.E. van Hellmond et al,
SABCS 2018 abstract P4-14-11

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, et al.
Lancet Oncol. 2017;18(11):1502-11.

Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.
Van Hellemond IEG, Vriens IJH, Peer PGM, Swinkels ACP, Smorenburg CH, Seynaeve CM, et al.
J Natl Cancer Inst. 2017;109(12).

BOOG 2006-02 / OMEGA
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG
C. H. Smorenburg; S. M. de Groot; A. E. van Leeuwen-Stok; M. E. Hamaker; A. N. Wymenga; H. de

Graaf; F. E. de Jongh; J. J. Braun; M. Los; E. Maartense; H. van Tinteren; J. W. R. Nortier; C. Seynaeve
Annals of Oncology 2014; doi: 10.1093/annonc/mdt588

Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group
M.E. Hamaker, C. Seynaeve, A.N.M. Wymenga, H. van Tinteren, J.W.R. Nortier, E. Maartense, H. de Graaf, F.E. de Jongh, J.J. Braun, M. Los, J.G. Schrama, A.E. van Leeuwen-Stok, S.M. de Groot, C.H. Smorenburg.
Breast 2013;xx: 1-7

Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study
M.E. Hamaker, C. Seynaeve, J.W.R. Nortier, M. Wymenga, E. Maartense, E. Boven, A.E. van Leeuwen-Stok, S.E. de Rooij, B.C. van Munster, C.H. Smorenburg
Breast 2013;22:556-9.

First-line chemotherapy with pegylated liposomal doxorubicin (PEGdoxo) versus capecitabine (Cape) in elderly patients with metastatic breast cancer: results of the phase III OMEGA study of the Dutch Breast Cancer Trialists' Group (BOOG)
C.H. Smorenburg, C. Seynaeve, A.N.M. Wymenga, E. Maartense, H. de Graaf, F.E. de Jongh, J.J. Braun, M. Los, J.G. Schrama, J.E.A. Portielje, M. Hamaker, H. van Tinteren, S.M. de Groot, A.E. van Leeuwen-Stok, J.W.R. Nortier
Poster SABCS 2012

Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review
Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC.
Lancet Oncol 2012;Vol 13:Issue 11, e437-44.

Resultaten van de klinische studie gepresenteerd op een congres/symposium:
Baseline comprehensive geriatric assessment predicts for toxicity of single agent chemotherapy in elderly metastatic breast cancer patients: results from the OMEGA study of the Dutch Breast Cancer Trialists' Group
M.E. Hamaker, C. Seynaeve, A.N.M. Wymenga, H. van Tinteren, J.W.R. Nortier, E. Maartense, S.M. de Groot, C.H. Smorenburg
ASCO 2012 accepted as poster presentation

Toxicities and feasibility associated with PEG doxo versus Capecitabine (Cape) as first line chemotherapy in elderly metastatic breast cancer patients (OMEGA trial)
C. Seynaeve, H. van Tinteren, ANM Wymenga, JWR Nortier, E. Maartense, FE de Jongh, H. de Graaf, SM de Groot, JJ Braun, CH Smorenburg
EBCC-8 2012 accepted as poster presentation

Reasons for low accrual of elderly patients with metastatic breast cancer in the OMEGA study of the Dutch Breast cancer Trialists' Group (BOOG).
ME Hamaker, C Seynaeve, ANM Wymenga, JWR Nortier, E Maartense, FE de Jongh, H de Graaf, JJ Braun, SM de Groot, AE van Leeuwen-Stok, CH Smorenburg
SIOG November 2011 accepted as oral presentation

De OMEGA studie. Een gerandomiseerde fase III-studie betreffende eerstelijnschemotherapie met gepegyleerd liposomaal doxorubicine of capecitabine bij patienten vanaf 65 jaar met gemetastaseerd mammacarcinoom, inclusief geriatrische evaluatie.
CH Smorenburg, ANM Wymenga, E Maartense, JWR Nortier, C Seynaeve.
Ned Tijdschrift Oncol 2009;6:275-8

Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.
Hamberg P, Verweij J, Seynaeve C.
Eur J Cancer. 2007 Jul;43(10):1514-28.

BOOG 2006-03 / SUPREMO
Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial
G.Velikova, L.J. Williams, S.Willis, J.M. Dixon, J. Loncaster, M. Hatton, et al
Lancet Oncology, V 19, issue 11, p1516-1529, November 01, 2018

Pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.
Thomas JS, Hanby AM, Russell N, van Tienhoven G, Riddle K, Anderson N, Cameron DA, Bartlett JM, Piper T, Cunningham C, Canney P, Kunkler IH; SUPREMO Trial Management Group.
Breast Cancer Res Treat. 2017 May;163(1):63-69.

European interpretation of North American post mastectomy radiotherapy guideline update.
Kunkler IH, Dixon JM, Maclennan M, Russell NS.
Eur J Surg Oncol 2017;43(10):1805-7.

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.
Thomas JS, Hanby AM, Russell N, van Tienhoven G, Riddle K, Anderson N, Cameron DA, Bartlett JM, Piper T, Cunningham C, Canney P, Kunkler IH; SUPREMO Trial Management Group.
Breast Cancer Res Treat. 2017 May;163(1):63-69. doi: 10.1007/s10549-017-4145-4. Epub 2017 Feb 11.

The SUPREMO Trial – Pathology quality assurance of a large phase III randomised international clinical trial.
Jeremy Thomas, Andrew Hanby, Nicola Russell, Geertjan van Tienhoven, Kathleen Riddle, David Cameron, John Bartlett, Tammy Piper, Carrie Cunningham, Peter Canney, Ian Kunkler.
EBCC-10 2016 poster presentation.

Determining the indications for post mastectomy radiotherapy: moving from 20th century clinical staging to 21st century biological criteria.
Russell NS, Kunkler IH, van Tienhoven G.
Ann Oncol. 2015 Jun;26(6):1043-4.

Post-mastectomy radiotherapy- will SUPREMO end the debate?

Russell NS, Kunkler I, van Tienhoven G, Canney PA, Thomas J, Bartlett, J van de Vijver MJ, Belkacemi Y, Yarnold JR, Barrett-lee PJ. J.
Clin Oncol 2009; 27 (6): 996-7.

SUPREMO trial management group. Elucidating the role of chest wall irradiation in "intermediate-risk" breast cancer: the MRC/EORTC SUPREMO trial.
I.H. Kunkler, P. Canney, G. Van Tienhoven, N.S. Russell on behalf of the MRC/EORTC (BIG 2-04)
Clin Oncol 20: 31-34, 2008.

BOOG 2006-04 / TEAM-II
TEAM IIA
Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer.
Inda MA, Blok EJ, Kuppen PJK, Charehbili A, den Biezen-Timmermans EC, van Brussel A, Fruytier SE, Meershoek-Klein Kranenbarg E, Kloet S, van der Burg B, Martens JWM, Sims AH, Turnbull AK, Dixon JM, Verhaegh W, Kroep JR, van de Velde CJH, van de Stolpe A.*Mol Cancer Ther. 2020 Feb;19(2):680-689. doi: 10.1158/1535-7163.MCT-19-0318. Epub 2019 Nov 14.*

Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).
Fontein DB, Charehbili A, Nortier JW, Putter H, Meershoek-Klein Kranenbarg E, Kroep JR, Linn SC, van de Velde CJH.
Eur J Surg Oncol. 2017 Apr;43(4):619-624.

ER pathway activity as a predictive biomarker for neoadjuvant endocrine therapy. Blok et al.
SABCS 2016 P3-07-65.

Radiological evaluation of neo-adjuvant endocrine therapy in hormone-receptor positive early breast cancer. Blok et al.
SABCS 2016 P6-01-05.

TEAM IIB
Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with hormone receptor positive breast cancer (BOOG 2006-04): randomized phase 3 TEAM-IIB trial
Vliek SB, Noordhoek I, Meershoek-Klein Kranenbarg E, van Rossum AGJ, Dezentje VO, Jager A, Hokken JWE, Putter H, van der Velden AWG, Hendriks MP, Bakker SD, van Riet YEA, Tjan-Heijnen VCG, Portielje JEA, Kroep JR, Nortier JWR, van de Velde CJH, Linn SC.
J Clin Oncol. 2022 Sep 1;40(25):2934-2945. doi: 10.1200/JCO.21.00311

Abstract SABCS 2016 poster discussion

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R.
Lancet. 2015 Oct 3;386(10001):1353-61.

Efficacy of six months neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - a phase II trial

D.B.Y.Fontein, C.J.H.van de Velde, A.Charehbili, W.M.Meershoek-Klein Kranenbarg, J.W.R.Nortier, J.R.Kroep, H.Putter, G.J.Liefers, S.C.Linn, Y. van Riet, G. Nieuwenhuijzen, B. de Valk, J.M. Meerumterwogt, G. Algie
Eur J Cancer 2014

BOOG 2006-05 / IDEAL
Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy.
Noordhoek I, Treuner K, Putter H, Zhang Y, Wong J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, van de Velde CJH, Schnabel CA, Liefers GJ.Clin *Cancer Res. 2021 Jan 1;27(1):311-319. doi: 10.1158/1078-0432.CCR-20-2737. Epub 2020 Oct 27.*

Breast Cancer Index and prediction of benefit from extended endocrine therapy based on treatment compliance: An IDEAL study
ASCO 2021

An optimized Breast Cancer Index node-positive (BCIN+) prognostic model for late distant recurrence in patients with hormone receptor-positive (HR+) node-positive breast cancer.
ESMO 2021

EDITORIAL
Searching for the IDEAL Duration of Adjuvant Endocrine Therapy
Rachel L. Yung, Nancy E. Davidson
JNCI J Natl Cancer Inst (2018)

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok, Judith R. Kroep, Elma Meershoek-Klein Kranenbarg,Marjolijn Duijm-de Carpentier, Hein Putter, Joan van den Bosch,Eduard Maartense, A. Elise van Leeuwen-Stok, Gerrit-Jan Liefers,
Johan W.R. Nortier, Emiel J.Th. Rutgers, Cornelis J.H. van de Velde; on behalf of the IDEAL Study Group
JNCI J Natl Cancer Inst (2018)

Optimal duration of extended adjuvant endocrine therapy for early breast cancer.
Blok E, Kroep J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, Maartense E, van Leeuwen-Stok E, Liefers G, Nortier J, Rutgers E, van de Velde CJH, on behalf of the IDEAL Study Group
J Natl Cancer Inst. 2017, Mid July on-line

Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)
van de Velde CJH, Blok E, Meershoek-Klein Kranenbarg E, Putter H, van den Bosch J, Maartense E, Duijm-de Carpentier M, van Leeuwen-Stok E, Liefers G, Nortier J, Rutgers E, Kroep J
ECCO abstract January 2017

Abstracts SABCS 2016 oral presentation and poster

High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.

Fontein DBY, Nortier JWR, Liefers GJ, Putter H, Meershoek-Klein Kranenbarg E, van den Bosch J, Maartense E, Rutgers EJTh, van de Velde CJH.
Eur J Surg Oncol. 2012 Feb;38(2):110-7. Epub 2011 Dec 14.

High Rates of Nonadherence to Aromatase Inhibitors in the Extended Adjuvant Setting
DBY Fontein, JWR Nortier, H Putter, E Meershoek-Klein Kranenbarg, EJTh Rutgers, CJH van de Velde
Poster #: 5.162 op ECCO 16, 24-27 September 2011, Stockholm

Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients.
Kool M, Fontein DB, Meershoek-Klein Kranenbarg E, Nortier JW, Rutgers EJ, Marang-van de Mheen PJ, van de Velde CJH.
Breast. 2015 Jun;24(3):224-9.

Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.
Blok EJ, Derks MG, van der Hoeven JJ, van de Velde CJH, Kroep JR.
Cancer Treat Rev. 2015 Mar;41(3):271-6.

BOOG 2006-06 / ATX
Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
Lam SW, Frederiks CN, van der Straaten T, Honkoop AH, Guchelaar HJ, Boven E.
Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.326.

The role of pharmacogenetics in capecitabine efficacy and toxicity.
Lam SW, Guchelaar HJ, Boven E.
Cancer Treat Rev. 2016 Aug 10;50:9-22. doi: 10.1016/j.ctrv.2016.08.001. Review.

Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy.
Lam SW, Nota NM, Jager A, Bos MM, van den Bosch J, van der Velden AM, Portielje JE, Honkoop AH, van Tinteren H, Boven E; ATX Trial Team..
Clin Cancer Res. 2016 Apr 1;22(7):1611-20. doi: 10.1158/1078-0432.CCR-15-1005.

Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
Frederiks CN, Lam SW, Guchelaar HJ, Boven E.
Cancer Treat Rev. 2015 Dec;41(10):935-50. doi: 10.1016/j.ctrv.2015.10.010. Review.

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW, de Groot SM, Honkoop AH, Jager A, ten Tije AJ, Bos MM, Linn SC, van den Bosch J, Kroep JR, Braun JJ, van Tinteren H, Boven E; Dutch Breast Cancer Research Group.
Eur J Cancer. 2014 Dec;50(18):3077-88.

Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
Siu W Lam1, Nienke M Nota1, Steffen M de Groot2, Agnes Jager3, Monique MEM Bos4, Sabine C Linn5, Joan van den Bosch6, Hans J Braun7, Ankie MT van der Velden8, Maartje Los9, Johanneke EA Portielje10, Judith R Kroep11, Aafke H Honkoop12, Carolien H Smorenburg13, Bea Tanis14, Johanna MGH van Riel15, Jetske M Meerum Terwogt16, Marien O den Boer17, Joep Douma18, Frank Jeurissen19, Johan Berends20, Harm van Tinteren5 and Epie Boven1.
SABCS 2014, publication number P3-06-09

Genetic polymorphisms (SNPs) as predictive markers for paclitaxel-induced peripheral neuropathy (PNP) and capecitabine-induced hand-foot syndrome (HFS) in HER-2 negative metastatic breast cancer patients
Siu W Lam1, Charlotte N Frederiks1, Tahar van der Straaten2, Steffen M de Groot3, Agnes Jager4, Monique MEM Bos5, Sabine C Linn6, Joan van den Bosch7, Hans J Braun8, Ankie MT van der Velden9, Maartje Los10, Jojanneke EA Portielje11, Judith R Kroep2, Aafke H Honkoop12, Carolien H Smorenburg13, Bea Tanis14, Johanna MGH van Riel15, Jetske M Meerum Terwogt16, Marien O den Boer17, Joep Douma18, Frank Jeurissen19, Johan Berends20, Henk-Jan Guchelaar2 and Epie Boven1.
SABCS 2014 publication number P6-08-09

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial
S.W. Lam, S.M. de Groot, A.H. Honkoop, A. Jager, A.J. ten Tije, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.R. Kroep, J.J. Braun, H. van Tinteren, E. Boven, on behalf of the Dutch Breast Cancer Research Group (BOOG).
Eur J Cancer 2014 (conditionally accepted)

Plasma VEGF-A, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
S.W. Lam, S.M. de Groot, A.H. Honkoop, N.M. Nota, A. Jager, A.W.T van der Velden, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.R. Kroep, J.J. Braun, R.R. de Haas, C.H. Smorenburg, H. de Graaf, J.E.A. Portielje, M. Los, D.D. Gooyer, H. van Tinteren and E. Boven.
J Clin Oncol 31, 2013 (suppl; abstr 1072)

Plasma VEGF-A, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
S.W. Lam, S.M. de Groot, A.H. Honkoop, N.M. Nota, A. Jager, A.W.T van der Velden, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.R. Kroep, J.J. Braun, R.R. de Haas, C.H. Smorenburg, H. de Graaf J.E.A. Portielje, M. Los, D.D. Gooyer, H. van Tinteren and E. Boven.
Abstract ASCO 2013

Combination of paclitaxel and bevacizumab without or with capecitabine as first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): first results from a randomized, multicenter, open-label, phase II study of the Dutch Breast Cancer Trialists' Group (BOOG) (abstract)

S.W. Lam, S.M. de Groot, A.H. Honkoop, A. Jager, A.J. ten Tije, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.W.R. Nortier, J.J. Braun, H. de Graaf, J.E.A. Portielje, M. Los, D.D. Gooyer, H. van Tinteren, E. Boven, *SABCS 2011*

BOOG onderzoekt combinatie bevacizumab met chemotherapie bij mammacarcinoom
E. Boven, A.H. Honkoop, H. van Tinteren C.L. van der Wilt, A.E. van Leeuwen-Stok
NvMO tijdschrift, 2008

ATX-studie: een multicentrische gerandomiseerde fase II BOOG-studie naar de behandeling van HER2-negatief gemetastaseerd mammacarcinoom.
E. Boven, A.H. Honkoop, C.L. van der Wilt, A.E. van Leeuwen-Stok
Ned. Tijdschrift voor Oncologie, 2007, Vol.4, nr. 8, p. 376-378.

BOOG 2006-07 / MIRROR
Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells.
M.J. Pepels, M. de Boer, P. Bult, J.A.A.M. van Dijck, C.H.M. van Deurzen, M.B.E. Menke-Pluymers, P.J. van Diest, G.F. Borm, and V.C.G. Tjan-Heijnen
Ann Surg, in press

Prognostic impact of isolated tumor cells in breast cancer axillary nodes: single tumor cell(s) versus tumor cell cluster(s) and microanatomic location.
J.H.M.J. Vestjens, M. de Boer, P.J. van Diest, C.H.M. van Deurzen, J.A.A.M. van Dijck, G.F. Borm, E.M.M. Adang, P. Bult, and V.C.G. Tjan-Heijnen.
Breast Cancer Res Treat, in press

Relevant impact of central pathology review on nodal classification, but not on the association of small nodal metastases with breast cancer outcome. Results from the Dutch MIRROR study.
J.H.M.J. Vestjens, M. de Boer, G.F. Borm, C.H.M. van Deurzen, P.J. van Diest, J.A.A.M. van Dijck, E.M.M. Adang, J.W.R. Nortier, E.J.T.Rutgers C. Seynaeve, M.B.E. Menke-Pluymers, P. Bult, and V.C.G. Tjan-Heijnen
Abstract PD06-04, poster presentation. San Antonio Breast Cancer Conference 2010, San Antonio, Texas, USA.
Cancer Res; 70(24 Suppl) Dec 15, 2010; PD06-04.

Cost-effectiveness of adjuvant systemic therapy in early-stage breast cancer patients with isolated tumor cells or micrometastases in regional lymph nodes.
M. de Boer, E.M.M. Adang, K. C. Van Dycke, J A.A.M. van Dijck, G.F. Borm, C.H.M. van Deurzen, P.J. van Diest, P. Bult, A.R.T. Donders, V.C.G. Tjan-Heijnen.
Abstract #614, poster presentation. ASCO Annual Meeting 2010, Chicago, Illinois, USA.
J Clin Oncol 28:15s, 2010.

Micrometastases and isolated tumor cells in breast cancer are indeed associated with poorer outcome.
P.J. van Diest, M. de Boer, C.H.M. van Deurzen, V.C.G. Tjan-Heijnen.
J Clin Oncol 2010; 28(9):e140; author reply e141-2.

Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): Results from the MIRROR study.
M. de Boer, C.H.M. van Deurzen, J.A.A.M. van Dijck, G.F. Borm, P.J. van Diest, E.M.M. Adang, J.W.R. Nortier, E.J.Th. Rutgers, C.Seynaeve, M.B.E. Menke-Pluymers, P. Bult, V.C.G. Tjan-Heijnen
Abstract #CRA506, oral presentation, ASCO Annual Meeting 2009, Orlando, Florida, USA.
J Clin Oncol 27:18s, 2009.

Isolated tumor cells in axillary lymph nodes of breast cancer patients: differential prognostic impact of single tumor cell(s) versus tumor cell clusters, and microanatomic location. New results from the Dutch MIRROR study.
P.J. van Diest, H. Schut, M. de Boer, C.H.M. van Deurzen, J.A.AM. van Dijck, G.F. Borm, E.M.M. Adang, P. Bult, and V.C.G. Tjan-Heijnen.
Abstract #306, poster discussion session. San Antonio Breast Cancer Conference 2009, San Antonio, Texas, USA.

Isolated Tumor Cells in Breast Cancer
Correspondence to the editor, N Engl J Med 361:1994-1996, November 12, 2009

Minimal lymph node involvement and outcome of breast cancer. The results of the Dutch MIRROR study.Tjan-Heijnen VC, de Boer M.
Discov Med. 2009 Oct;8(42):137-9.

Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer
M. de Boer, C.H.M. van Deurzen, J.A.A.M. van Dijck, G.F. Borm, P.J. van Diest, E.M.M. Adang, J.W.R. Nortier, E.J.Th. Rutgers, C. Seynaeve, M.B.E. Menke-Pluymers, P. Bult, V.C.G. Tjan-Heijnen.
N Engl J Med 361:653-63, August 13, 2009

Micrometastases and isolated tumor cells: relevant and robust or rubbish? (MIRROR): preliminary results of the MIRROR study from the Dutch breast cancer trialists' group (BOOG).
M. de Boer, C.H.M. van Deurzen, J.A.A.M. van Dijck, G.F. Borm, P.J. van Diest, E.M.M. Adang, J.W.R. Nortier, E.J.Th. Rutgers, C. Seynaeve, M.B.E. Menke-Pluymers, P. Bult, V.C.G. Tjan-Heijnen.
Abstract #23, oral presentation. San Antonio Breast Cancer Conference 2008, San Antonio, Texas, USA.

BOOG 2007-01 / ALLTO
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
De Azambuja E, Piccart-Gebhart M, Fielding S, et al.
ESMO Open. 2024;9(11):103938. doi:10.1016/j.esmoop.2024.103938
https://www.esmoopen.com/article/S2059-7029(24)01708-3/fulltext

Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial
Nature Communications 29 November 2024, Vol. 15, Article number: 10402 (2024)

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study
Diogo Martins-Branco et al.
Breast Cancer Res Treat. 2024. 203(3); 497-509 doi:10.1007/s10549-023-07159-9

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
Agostinetto E, Ameye L, Martel S, et all. PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. *ALTTO (BIG 2-06) Publication in npj Breast Cancer, 20 July 2022. npj Breast Cancer, 20 July 2022.* PMID: 35859079 NPJ Breast – Matteo Lambertini – AD 0107 **Abstract Title: Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials. Session Type/Title: Poster Discussion Session/ Breast Cancer—Local/Regional/Adjuvant**
Aranzazu Fernandez-Martinez
June 6, 2022, 1:15 PM-2:45 PM; 8:00 AM-11:00 AM CDT

Abstract 522: Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial
Carmine De Angelis, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Lieveke Ameye, Marianne Paesmans, Sarra El-Abed, Anup Choudhury, Sylvia Napoleone, Saranya Chumsri, Martine J. Piccart-Gebhart, Alvaro Moreno-Aspitia, Henry Leonidas Gomez, Giuseppe Viale, Susan G. Hilsenbeck, Mothaffar F. Rimawi, C. Kent Osborne, Evandro de Azambuja, Rachel Schiff
June 6, 2022, 8:00 AM-11:00 AM CDT, Poster ASCO Am AD0005

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)
FlorentineHilbers, SarraEl-Abed, Vasiliki Balta, Celine Schurmans, Daniela D.Rosa, Kamal Saini, Otto Metzger Filho, Robin McConnell, Vicki Paterson, Christine Campbell, Eleanor McFadden, Emma Paterson, Garrick Kassab, *Presented at the 2017 annual meeting of the American Society of Clinical Oncology. European Journal of Cancer,Volume 148, May 2021, Pages 287-296*

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: Analysis from the ALTTO (BIG 2-06) trial
Matteo Lambertini et al; *SABCS 2020 PD3-04*

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.
Eiger D, Pondé NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers FS, Werner O, Chumsri S, Dueck A, Kroep JR, Gomez H, Láng I, Rodeheffer RJ, Ewer MS, Suter T, de Azambuja E
Br J Cancer. 2020 Mar 16. doi: 10.1038/s41416-020-0786-x. [Epub ahead of print]

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials
Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber RD, de Azambuja E, Ignatiadis M
Cancer. 2019 Jan 15 doi: 10.1002/cncr.31784.

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial
Lambertini M, Campbell C, Gelber RD, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart M, Loi S, de Azambuja E *Breast Cancer Res Treat. 2019 May 27 doi: 10.1007/s10549-019-05284-y*

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO Trial
Holmes EM, Bradbury I, Williams LS, Korde L, de Azambuja E, Fumagalli D, Moreno-Aspitia A, Baselga J, Piccart-Gebhart M, Dueck AC, Gelber RD
Ann Oncol. 2019 Jun 26.; doi: 10.1093/annonc/mdz195.

Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials
Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers F, Schuehly U, Korde L, Azim H. A., Di Cosimo S, Tenglin R. C., Bodo Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M. J., Gelber R. D., De Azambuja E., Ignatiadis M
Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 10065-10065

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart M, Gelber RD, de Azambuja E
J Natl Cancer Inst. 2018 Jun 5. doi: 10.1093/jnci/djy094

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes
C F. Spraggs, LR Parham, L P Briley, L Warren, L S Williams, D Fraser, Z Jiang, Z Aziz, S Ahmed, G Demetrious, Z Tong, A O. Mehta, N Jackson, J Byrne, M Andersson, M Toi, L Harris, J Gralow, JA Zujewski, R Crescenzo, A Armour, E Perez, M Piccart
Pharmacogenomics J. 2018 May 22;18(3):480-486

Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial
Martel S, Lambertini M, Agbor-Tarh D, Ponde N, Gombos A, Paterson V, Hilbers F, Korde L, Manukyants A, Dueck A. C., Maurer C, Piccart-Gebhart M. J., Moreno-Aspitia A, Desmedt C, Di Cosimo S, De Azambuja E
Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 10067-10067

Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06)
M. Lambertini C. Campbell J. Bines L. Korde M.A. Izquierdo Delso D. Fumagalli K. Pritchard A. Wolff C. Jackisch I. Lang M. Untch I. Smith F.M. Boyle B. Xu C.H. Barrios J. Baselga A. Moreno-Aspitia M. Piccart R. Gelber E. De Azambuja
Ann Oncol. 2017 Sept 1 doi: 10.1093/annonc/mdx362.009

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial
Sonnenblick A., Agbor-Tarh D., Bradbury I., Di Cosimo S., Azim H. A., Fumagalli D., Sarp S., Wolff A. C., Andersson M., Kroep J., Cufer T., Simon S. D., Salman P., Toi M., Harris L., Gralow J., Keane M., Moreno-Aspitia A., Piccart-Gebhart M., de Azambuja E.
J Clin Oncol. 2017 May 1;35(13):1421-1429

Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.
A Moreno-Aspitia, E McCormick Holmes, C Jackisch, E De Azambuja, F. M. Boyle, D W. Hillman,
J.of Clinical Oncology 35, no. 15_suppl (May 2017) 502-502.

Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial
Minetta C Liu1, Brigitte Rack2, Amylou C Dueck4, David W Hillman1, Michael B Campion1, Monica M Reinholz3, Kevin C Halling1, Christos Sotiriou5, Françoise Rothé5, Marion Maetens5, Ghizlane Rouas5, Wolfgang Janni6, Antonio C Wolff7, Lyndsay N Harris8, Julie R Gralow9, Kathleen I Pritchard10, Susan Ellard12, Nguyet A Le-Lindqwister13, Frances Boyle14, Evandro De Azambuja5, Martine J Piccart-Gebhart5, Michail Ignatiadis5 and Edith A Perez11.
SABCS 2014, publication number: P4-01-01

Concordance of HER2 Central Assessment by Two International Central Laboratories: A Ring Study within the Framework of the Adjuvant HER2-Positive ALTTO Trial
McCullough AE, Dell'Orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Lingle WL, Jackisch C, Perez EA, Piccart-Gebhart MJ, Viale G.
Cancer Res; 70(24 Suppl) Dec 15, 2010; P3-10-06

Adjuvant Lapatininb en/of Trastuzumab Treatment Optimalization studie (ALTTO, BOOG 2007-01)
J.W.R.Nortier, *NTvO juni 2009*

The new generation of breast cancer clinical trials: the right drug for the right target].
De Azambuja E, Cardoso F, Meirsman L, Straehle C, Dolci S, Vantongelen K, Piccart-Gebhart M.
Bull Cancer. 2008 Mar;95(3):352-7. Review. French.

Jumping higher: is it still possible? The ALTTO trial challenge
G. Tomassello, E. de Azambuja, P. Dinh,N. Snoj and M. Piccart-Gebhart; *Expert Rev. Anticancer Ther. 8(12), 1883-1890 (2008)*

BOOG 2007-02 / INTENS
Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer
Vriens BE, Aarts MJ, de Vries B, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Borm GF, Tjan-Heijnen VC; Breast Cancer Trialists'.
Eur J Cancer 2013 Oct;49(15):3102-10

Neoadjuvant chemotherapy and pathologic complete response in relation to clinical response, results from a phase III study (INTENS) of the Dutch breast cancer trialists' group (BOOG).
VCG Tjan-HeijnenA, BEPJ VriensA, B de VriesA, SM van GastelB, J WalsC, TJ SmildeD, LJC van WarmerdamE, HWM van LaarhovenF , DJ van SpronsenG, GF BormF
SABCS 2012

Sequential versus upfront intensified neoadjuvant chemotherapy in patients with large resectable or locally advanced breast cancer (INTENS), toxicity results from a phase III study of the Dutch breast cancer trialists' group (BOOG).
Vriens BEPJ, Van de Vijver KKBT, Boetes C, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJC, van Laarhoven HWM, van Spronsen DJ, Borm GF, Tjan-Heijnen VCG.
Cancer Res; 71 (24 Suppl) Dec 15, 2011

Sequential versus upfront intensified neoadjuvant chemotherapy in patients with large resectable or locally advanced breast cancer (INTENS), first results from a phase III study of the Dutch breast cancer trialists' group (BOOG).
Vriens BE, Van de Vijver KK, Boetes C, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJ, van Laarhoven HW, van Spronsen DJ, Borm GF, Tjan-Heijnen VCG.
Cancer Res; 70(24 Suppl) Dec 15, 2010;

BOOG 2008-01 / 2-2-6 G-CSF
Primary Granulocyte Colony-Stimulating Factor for Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in patients with breast cancer at risk for febrile neutropenia
M.J. Aarts, F.P. Peters, C.M. Mandigers, M.W. Dercksen, J.M. Stouthard, J.W.R. Nortier, H.W. van Laarhoven, L.J. van Warmerdam, A.J. van de Wouw, E.M. Jacobs, V. Mattijssen, C.C. van der Rijt, T.J. Smilde, A.W. van der Velden, M. Temizkan, E. Batman, E.W. Muller, S.M. van Gastel, G.F. Borm, V.C. Tjan-Heijnen,.
J Clin Oncol 2013; April 29, [Epub ahead of print]

Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC.
J Clin Oncol. 2013 Dec 1;31(34):4283-9. doi: 10.1200/JCO.2012.48.3644. Epub 2013 Oct 28.

Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC.
J Clin Oncol. 2013 Dec 1;31(34):4290-6. doi: 10.1200/JCO.2012.44.6229. Epub 2013 Apr 29

Primary G-CSF prophylaxis during the first two cycles only or throughout all chemotherapy cycles in breast cancer patients at risk of febrile neutropenia.

Aarts MJ, Peters FP, Mandigers CM, Dercksen WM, Stouthard JM, Nortier JWR, van Laarhoven HWM, van Warmerdam LJ, van de Wouw YA, Jacobs EM, Mattijssen VE, van der Rijt CCD, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van der Vegt SG, van Gastel SM, Borm GF, Tjan-Heijnen VCG,
(2012) (submitted)

Primary G-CSF prophylaxis during the First Two cycles only or Throughout All chemotherapy cycles in breast cancer patients at risk of Febrile Neutropenia: First results from a phase III trial of the Dutch Breast Cancer Trialists Group (BOOG)
M.J.B. Aarts, F.P.J. Peters, M.W. Dercksen, C. Mandigers, S. van Gastel, V.C.G. Tjan-Heijnen
Support Care Cancer 2010;18 (Suppl 3):S 09-078

Primary G-CSF prophylaxis during the First Two cycles only or Throughout All chemotherapy cycles in breast cancer patients at risk of Febrile Neutropenia: Final results from a phase III trial of the Dutch Breast Cancer Trialists Group (BOOG)
M.J.B. Aarts, F.P.J. Peters, M.W. Dercksen, C.Mandigers, J.Stouthard, J.W.R. Nortier, Y.J.L. Kamm, L.J.C. van Warmerdam, C.D. van der Rijt, S. van Gastel, M. Joore, A. Kessels, V.C.G. Tjan-Heijnen
Cancer Res; 2010;70(24) Suppl2; P3-15-01

BOOG 2008-02 / A6181099 (SUTENT)
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.
Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M.
Breast Cancer Res Treat. 2010 May;121(1):121-31. Epub 2010 Mar 26.

Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).
J. Crown, V. Dieras, E. Staroslawska, D. A. Yardley, N. Davidson, T. D. Bachelot, V. R. Tassell, X. Huang, K. A.Kern, G. Romieu;
J Clin Oncol 28:18s, 2010 (suppl; abstr LBA1011)

BOOG 2008-03 / HAT
A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Drooger JC, van Tinteren H, de Groot SM, Ten Tije AJ, de Graaf H, Portielje JE, Jager A, Honkoop A, Linn SC, Kroep JR, Erdkamp FL, Hamberg P, Imholz AL, van Rossum-Schornagel QC, Heijns JB, van Leeuwen-Stok AE, Sleijfer S.
Cancer. 2016 Oct;122(19):2961-70. doi: 10.1002/cncr.30141. Epub 2016 Jun 17.

Results from a randomized phase II study of the Dutch Breast Cancer Research Group (BOOG 2008-03): Concomitant trastuzumab, bevacizumab and paclitaxel (HAT) versus trastuzumab and bevacizumab, followed by trastuzumab, bevacizumab and paclitaxel (HA-HAT) at progression as first-line treatment for patients with Her2 positive metastatic breast cancer: The HAT-Study
Jan C Drooger1, Harm van Tinteren2, Steffen M de Groot3, Albert J ten Tije4, Hiltje de Graaf5, Johanneke EA Portielje6, Agnes Jager1, Aafke H Honkoop7, Sabine C Linn2, Judith R Kroep8, Frans LG Erdkamp9, Paul Hamberg10, Joan B Heijns4, A Elise van Leeuwen-Stok11 and Stefan Sleijfer1.

SABCS 2014, publication number: P4-15-12

BOOG 2008-03/HAT-studie: Een gerandomiseerde fase II-studie bij patiënten met gemetastaseerde **borstkanker met Her2/neu-overexpressie**
J.Ph. van den Tol en S. Sleijfer;
NTvO, 2009, Vol.6 nr 8:365-66

BOOG 2009-01 / IRMA
APBI with 3D-CRT vs. WBI: primary endpoint results of the prospective randomised phase 3 IRMA trial
Bruno Meduri, Antonella Baldissera, Cinzia Iotti,...Elisa D'Angelo, Philip Poortmans, Giovanni P. Frezza
ESTRO 2024 abstract

APBI with 3D-CRT vs. WBI: cosmetic and toxicity results of the prospective randomised IRMA trial
Antonella Baldissera., Filippo Bertoni., Gladys Blandino., Liesbeth Boersma., Selena Ciabatti., Roberto D'amico., Luca Frassinelli., Giovanni P. Frezza., Patrizia Giacobazzi., Cinzia Iotti., Eveline Koiter., Bruno Meduri., Alessio G. Morganti., Salvatore Parisi., Philip M.P. Poortmans., Marcel Stam., Mariacarla Valli.
ESTRO 2020 abstract

Cosmetic Results and Side Effects ofAccelerated Partial-Breast Irradiation VersusWhole-Breast Irradiation for Low-Risk InvasiveCarcinoma of the Breast: The Randomized PhaseIII IRMA Trial
runo Meduri, MD1; Antonella Baldissera, MD2; Cinzia Iotti, MD3; Luc J.E.E. Scheijmans, MD4; Marcel R. Stam, MD5;Salvatore Parisi, MD6; Liesbeth J. Boersma, MD7; Ilario Ammendolia, MD8; Eveline Koiter, MD9; Mariacarla Valli, MD10;Luciano Scandolaro, MD11; Dianne Busz, MD12; Marika C. Stenfert Kroese, MD13; Selena Ciabatti, MD2; Patrizia Giacobazzi, MD1;Maria P. Ruggieri, PhD3; Antoine Engelen, MD4; Tindara Munaf`o, MD6; A. Helen Westenberg, MD5; Karolien Verhoeven, MD7;Roberto Vicini, PhD14; Roberto D'Amico, PhD14,15; Frank Lohr, MD1; Filippo Bertoni, MD1; Philip Poortmans, MD16,17;andGiovanni P. Frezza, MD2
Journal of Clinical Oncology 2023

BOOG 2009-02 / SNARB
Sentinel Node and Recurrent Breast Cancer (SNARB): Results of a Nationwide Registration Study
Maaskant AJG, Roumen RMH, Voogd AC, Pijpers R, Luiten EJT, Rutgers EJT, Nieuwenhuijzen GAP
Annals of Surgical Oncology (2012), DOI 10.1245/s10434-012-2625-7

Staging and management of axillary lymph nodes in patients with local recurrence in the breast or chest wall after a previous negative sentinel node procedure
F.Derkx, A.J.G. Maaskant-Braat, M.J.C. van der Sangen, G.A.P. Nieuwenhuijzen, L.V. van de Poll-Franse, R.M.H. Roumen, A.C. Voogd
Eur J Surg Oncol (2010), doi:10.1016/j.ejso.2010.05.009

Schildwachtklierprocedure bij recidief mammacarcinoom (SNARB); resultaten van een interim-analyse
Maaskant AJG, Bruijn de S, Roumen RMH, Nieuwenhuijzen GAP
Catharina-ziekenhuis, Eindhoven, afdeling Heelkunde
Abstract Chirurgendagen NVH 21-05-2010

Schildwachtklierprocedure: ook een mogelijkheid bij patiënten met een recidief van een mammacarcinoom
R.M.H. Roumen, G.P. Kuijt en I.H. Liem
Ned Tijdschr Geneeskd. 2008;152:13-9

BOOG 2009-03 / DCIS
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study
Boon H Chua, Emma K Link, Ian H Kunkler, Timothy J Whelan, A Helen Westenberg, Guenther Gruber, Guy Bryant, Verity Ahern, Kash Purohit, Peter H Graham, Mohamed Akra, Orla McArdle, Peter O'Brien, Jennifer A Harvey, Carine Kirkove, John H Maduro, Ian D Campbell, Geoff P Delaney, Joseph D Martin, T Trinh T Vu, Thierry M Muanza, Anthony Neal, Ivo A Olivotto, on behalf of the BIG 3–07/TROG 07.01 trial investigators**Lancet 2022; 400: 431–40*

A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)
Boon Hui Chua, Emma Link, Ian Kunkler, Ivo Olivotto, Antonia Helen Westenberg, Timothy Whelan, Guenther Gruber
Cancer Res 2021 Feb;81(4_Suppl)
Abstract SABCS 2020

Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial
King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH, BIG 3-07/TROG 07.01 trial investigators
Lancet Oncol. 2020, Volume May 2020 Mar 20. doi: 10.1016/S1470-2045(20)30085-1.

International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast
Ivo A Olivotto, Emma Link, Claire Phillips, Timothy J Whelan, Guy Bryant, Ian H Kunkler, A Helen Westenberg, Kash Purohit, Verity Ahern, Peter H Graham, Mohammed Akra, Orla McArdle, Joanna J Ludbrook,Jennifer A Harvey,John H Maduro,Carine Kirkove, Guenther Gruber, Joseph D Martin,Ian D Campbell,Geoff P Delaney, Boon H Chua, on behalf of the BIG 3-07/TROG 07.01 trial investigators
Radiotherapy and Oncology 2020;142:180-85

Patient-reported outcomes in ductal carcinoma in situ (DCIS): A systematic review. King MT, Winters Z, Butow P, Chua B, Saunders C, Spillane A, Mann GB, Olivotto I, Westenberg AH, Burnett P, Rutherford C.
European Journal of Cancer 2016;71:95-108

DCIS:kunnen extra bestralingen borstkanker voorkomen?
Paul Peijnenbur, H. Westenberg
Bproefd BVN 6 midwinter 2012

BOOG 2009-04 / Male Breast cancer
NANOSTRING: **Evaluation of multiple transcriptomic gene risk signatures in male breast cancer.** Bayani J, Poncet C, Crozier C, Neven A, Piper T, Cunningham C, Sobol M, Aebi S, Benstead K, Bogler O, Dal Lago L, Fraser J, Hilbers F, Hedenfalk I, Korde L, Linderholm B, Martens J, Middleton L, Murray M, Kelly C, Nilsson C, Nowaczyk M, Peeters S, Peric A, Porter P, Schröder C,

Rubio IT, Ruddy KJ, van Asperen C, Van Den Weyngaert D, van Deurzen C, van Leeuwen-Stok E, Vermeij J, Winer E, Giordano SH, Cardoso F, Bartlett JMS.NPJ
Breast Cancer. 2021 Jul 26;7(1):98.

Elastosis in ERα-positive male breast cancer
Marijn A. Vermeulen, & Carolien H. M. van Deurzen, A. Elise van Leeuwen-Stok, Paul J. van Diest;
Virchows Archiv https://doi.org/10.1007/s00428-020-02920-7, published online 15 September 2020

High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer
Qiu SQ, van Rooijen J, Nienhuis HH et al.
Breast Cancer Res. 2020 Mar 18;22(1):30. doi: 10.1186/s13058-020-01266-x.

Clinical and biological characterization of Male Breast Cancer: an international retrospective EORTC, BIG and NABCG intergroup study.
Bayani J, Poncet C, Crozier C, Trinh QM, Hopkins M, Uwimana AL, Piper T, Cunningham C, Sobol M, Aebi S, Benstead K, Bogler O, Dal Lago L, Fraser J, Hilbers F, Hedenfalk I, Korde L, Linderholm B, Martens J, Middleton L, Murray M, Kelly C, Nilsson C, Nowaczyk M, Peeters S, Peric A, Porter P, Schröder C, Rubio IT, Ruddy KJ, van Asperen C, Van Den Weyngaert D, van Deurzen CHM, van Leeuwen-Stok E, Vermeij J, Winer E, Stein L, Giordano SH, Cardoso F, Bartlett JMS.
Poster presentation at the San Antonio Breast Cancer Symposium (SABCS), Texas, USA, December 10-14, 2019.

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Cardoso F[1,2], Bartlett JMS[3,4], Slaets L[5], van Deurzen CHM[6,7], van Leeuwen-Stok E[7], Porter P[8,9], Linderholm B[10,11], Hedenfalk I[12], Schröder C[7,13], Martens J[7,14], Bayani J[3], van Asperen C[7,15], Murray M[16], Hudis C[17,18], Middleton L[19], Vermeij J[20], Punie K[21], Fraser J[22], Nowaczyk M[23], Rubio IT[24], Aebi S[25], Kelly C[26], Ruddy KJ[27], Winer E[28], Nilsson C[29,30], Dal Lago L[31], Korde L[32], Benstead K[33], Bogler O[34], Goulioti T[35], Peric A[5], Litière S[5], Aalders KC[5], Poncet C[5], Tryfonidis K[5], Giordano SH[36].
Ann Oncol. 2018 Feb 1;29(2):405-417. doi: 10.1093/annonc/mdx651.

Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Vermeulen MA[1], Slaets L[2], Cardoso F[3], Giordano SH[4], Tryfonidis K[2], van Diest PJ[1], Dijkstra NH[5], Schröder CP[6], van Asperen CJ[7], Linderholm B[8], Benstead K[9], Foekens R[10], Martens JWM[11], Bartlett JMS[12], van Deurzen CHM[13].
Eur J Cancer. 2017 Sep;82:219-227. doi: 10.1016/j.ejca.2017.01.034. Epub 2017 Mar 11.

Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Doebar SC[1], Slaets L[2], Cardoso F[3], Giordano SH[4], Bartlett JM[5], Tryfonidis K[2], Dijkstra NH[6], Schröder CP[7,6], van Asperen CJ[8,6], Linderholm B[9], Benstead K[10], Dinjens WN[1], van Marion R[1], van Diest PJ[11], Martens JW[12,6], van Deurzen CH[1,6].
Mod Pathol. 2017 Apr;30(4):509-518.

Performance of **BRCA1/2 mutation prediction models** in **male breast cancer patients**.

Moghadasi S, Grundeken V, Janssen LAM, Dijkstra NH, Rodríguez-Girondo M, van Zelst-Stams WAG, Oosterwijk JC, Ausems MGEM, Oldenburg RA, Adank MA, Blom EW, Ruijs MWG, van Os TAM, van Deurzen CHM, Martens JWM, Schroder CP, Wijnen JT, Vreeswijk MPG, van Asperen CJ.
Clin Genet. 2018 Jan;93(1):52-59. doi: 10.1111/cge.13065. Epub 2017 Sep 25.

Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program
F. Cardoso, J. Bartlett, L. Slaets, C. van Deurzen, E. van Leeuwen-Stok, P. Porter, B. Linderholm, I. Hedenfalk, C. Schröder, J. Martens, J. Bayani, C. van Asperen, M. Murray, C. Hudis, L. Middleton, J. Vermeij, S. Peeters, J. Fraser, M. Nowaczyk, I.T. Rubio, S. Aebi, C. Kelly, K. Ruddy, E. Winer, C. Nisson, L. Dal Lago, L. Korde, K. Benstead, D. van den Weyngaert, O. Bogler, Th. Goulioti, N. Dif, C. Messina, K. Tryfonidis, J. Bogaerts and S. Giordano
SABCS 2014 - Abstract no. S6-05

Male breast cancer in the Netherlands: uptake and outcome of BRCA testing
Results of study the Dutch Breast Cancer Research Group (BOOG 2009-04) in collaboration with the EORTC 10085 study.
CJ van Asperen, N Dijkstra, PJM van Hees, WAG van Zelst-Stams, JC Oosterwijk, MGE Ausems, RA Oldenburg, MA Adank, EW Blom, M Ruijs, TAM van Os, LAM Janssen, CHM van Deurzen, S Roshani, JWM Martens, CP Schroder
European Society Human Genetics (ESHG 2014, Milaan) – Abstract no. P12.085-S.

BOOG 2009-05 / BOLERO-2
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME.
JAMA Oncol. 2016 Aug 11. doi: 10.1001/jamaoncol.2016.1279. [Epub ahead of print]

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J.
J Clin Oncol. 2016 Feb 10;34(5):419-26. doi: 10.1200/JCO.2014.60.1971. Epub 2015 Oct 26.

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study.
Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA 3rd, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart M.
Eur J Cancer. 2013 Aug;49(12):2621-32. doi: 10.1016/j.ejca.2013.04.011. Epub 2013 Jun 1.

Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI.
J Natl Cancer Inst. 2013 May 1;105(9):654-63. doi: 10.1093/jnci/djt026. Epub 2013 Feb 19.

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Burris HA 3rd, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S.
Cancer. 2013 May 15;119(10):1908-15. doi: 10.1002/cncr.28010. Epub 2013 Mar 15.

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T, Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y.
Breast Cancer. 2013 Feb 13. [Epub ahead of print]

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN.
N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7.

Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial
Baselga J, Campone M, Sahmoud T, Piccart M, Burris H, Rudo H, Noguchi S, Gnant M, Mukhopadhyay P, Hortobagyi G
Abstract ESMO 2011
Presentatie ECCO 2011

BOOG 2010-01 / NEO-ZOTAC
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
de Groot S, Pijl H, Charehbili A, van de Ven S, Smit VTHBM, Meershoek-Klein Kranenbarg E, Heijns JB, van Warmerdam LJC, Kessels LW, Dercksen MW, Pepels MJAE, van Laarhoven HWM, Vriens BEPJ, Putter H, Fiocco M, Liefers GJ, van der Hoeven JJM, Nortier JWR, Kroep JR; Dutch Breast Cancer Research Group.
Breast Cancer Res. 2019 Aug 28;21(1):97.

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is 1 associated with better tumor control in breast cancer patients treated with neoadjuvant 2 chemotherapy with or without zoledronic acid.
De Groot F, et al. Submitted 2018

Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies. Vriens BE, Keymeulen KB, Kroep JR, Charehbili A, Peer PG, de Boer M, Aarts MJ, Heuts EM, Tjan-Heijnen VC, The Dutch Breast Cancer Research Group Boog.
Oncotarget. 2017;8(28):46557-64

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
J.R. Kroep, A. Charehbili, R.E. Coleman, R.L. Aft, Y. Hasegawa, M.C. Winter, K. Weilbaecher, K. Akazawa, S. Hinsleyf, H. Putter, G.J. Liefers, J.W.R. Nortier, N. Kohno
European Journal of Cancer 54 (2016) 57-63

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group.
Breast Cancer Res. 2016 Jan 6;18(1):3

Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).
Charehbili A, Hamdy NA, Smit VT, Kessels L, van Bochove A, van Laarhoven HW, Putter H, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van der Hoeven JJ, van de Velde CJ, Nortier JW, Kroep JR; Dutch Breast Cancer Research Group (BOOG).
Breast. 2016 Feb;25:69-74.

Serum vit D levels and response to molecular subtypes in breast cancer.
Kroep J, Charehbili A, Hamdy N.
Breast. 2016 Jun;27:186.

Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, Kessels LW, van Laarhoven HW, Bos MM, van de Velde CJ, Gratama JW, Sieuwerts AM, Martens JW, Foekens JA, Sleijfer S.
Mol Cancer Ther. 2015 Mar;14(3):821-7.

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Janssen LG, Charehbili A, Dijkgraaf EM, Smit VT, Kessels LW, van BA, van Laarhoven HW, Meershoek-Klein KE, van Leeuwen-Stok AE, van de Velde CJ, Putter H, Nortier JW, van der Hoeven JJ, Pijl H, Kroep JR
Breast Cancer Res Treat 2015;149:461-466.

Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial.
Dekker TJ, Charehbili A, Smit VT, ten Dijke P, Kranenbarg EM, van de Velde CJ, Nortier JW, Tollenaar RA, Mesker WE, Kroep JR.
Mol Oncol. 2015 Jun;9(6):1120-8

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).

de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group.
Breast Cancer Res. 2016 Jan 6;18(1):3.

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.
Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Winter MC, Weilbaecher K, Akazawa K, Hinsley S, Putter H, Liefers GJ, Nortier JW, Kohno N.
Eur J Cancer. 2015 Dec 23;54:57-63.

Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.
Charehbili A, de Groot S, van der Straaten T, Swen JJ, Pijl H, Gelderblom H, van de Velde CJH, Nortier J, Guchelaar HJ, Kroep JR.
Pharmacogenomics. 2015 Jul;16(11):1-10.

Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01). Charehbili A, Hamdy NA, Smit VT, Kessels L, van Bochove A, van Laarhoven HW, Putter H, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van der Hoeven JJ, van de Velde CJH, Nortier JW, Kroep JR; Dutch Breast Cancer Research Group (BOOG).
Breast. 2015 Nov 21 [Epub ahead of print]

Op het SABCS had Stefanie de Groot een poster:
Insulin-like growth factor 1 receptor expression and polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial (BOOG 2010-01). de Groot S et al. *SABCS 2016, publication number P3-07-54.*

Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01)
S de Groot1, A Charehbili1, L GM Janssen1, E M Dijkgraaf1, V THBM Smit1, L W Kessels2, A van Bochove3, H WM van Laarhoven4, E Meershoek-Klein Kranenbarg1, A E van Leeuwen-Stok5, G J Liefers1, C JH van de Velde1, J WR Nortier1, J JM van der Hoeven1, H Pijl1 and J R Kroep1.
SABCS 2014, publication number: P3-06-50

Sentinel node procedure before or after neoadjuvant chemotherapy in clinically node negative or positive patients; results from 3 phase III studies of the Dutch breast cancer trialists' group (BOOG)
Vivianne C Tjan-Heijnen1, Birgitte E Vriens1, Maureen J Aarts1, Judith R Kroep2, Cock J van de Velde2, Gerrit-Jan Liefers2, Ayoub
Charehbili2, Petronella G Peer3 and Maaike de Boer1.
Abstract SABCS, publication number P2-01-03

Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
Charehbili A, van de Ven S, Smit VT, Meershoek-Klein Kranenbarg E, Hamdy NA, Putter H, Heijns JB, van Warmerdam LJ, Kessels L, Dercksen M, Pepels MJ, Maartense E, van Laarhoven HW, Vriens B, Wasser MN, van Leeuwen-Stok AE, Liefers GJ, van de Velde CJ, Nortier JW, Kroep JR.

Annals of Oncology. 2014 May; 25(5):998-1004

Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomized trials.
Colemen RE et al.
2013 San Antonio Breast Cancer Symposium. Abstract S4-07.

Clinical and pathological response after neoadjuvant chemotherapy with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer.
Charehbili A et al.
European Cancer Congress 2013- Oral presentation, Abstract No: 1858

NEO-ZOTAC: Efficacy of NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC*) A Dutch Breast Cancer Trialists' Groups (BOOG) study.*
Charehbili A, van de Ven S, Liefers GJ, Smit VTHBM, Putter H, Heijns JB, van Warmerdam LJ, Kessels L, Dercksen M, Pepels MJ, Maartense E , van Laarhoven H, Vriens B, Wasser MN, Hamdy NAT, Meershoek-Klein Kranenbarg EM, van Leeuwen-Stok AE, van de Velde CJH, Nortier JWR, Kroep JR.
ASCO Annual Meeting 2013 - Abstract No: 1028.

NEO-ZOTAC: Toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with orwithout ZOledronic acid for patients with HER2-negative large resectable or locally advanced breast cancer
van de Ven S, Charehbili A, Liefers GJ, Putter H, Heijns JB, van Warmerdam LJ, Kessels L, Dercksen M, Pepels MJ, Maartense E, van Laarhoven H, Vriens B, Smit VT, Wasser, Meershoek-Klein Kranenbarg E,
van Leeuwen-Stok AE, van de Velde CJH, Nortier JWR, Kroep JR
Abstract SABCS 2012 PD07-06

NEO-ZOTAC: A Phase III Randomized Trial with Neoadjuvant Chemotherapy (TAC) with or without Zoledronic Acid for Patients with HER2-Negative Large Resectable or Locally Advanced Breast Cancer.
Abstract SABCS 2011, Program Number: OT1-01-04

Een nieuwe rol voor bisfosfonaten in de behandeling van het mammacarcinoom; het anti-tumoreffect?
Van de Ven S, Kroep JR, Hamdy NAT, Sleeboom AP, Nortier JWR:
Ned Tijdschr Geneeskd. 2010;154:A1951

Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, Kessels LW, van Laarhoven HW, Bos MM, van de Velde CJH, Gratama JW, Sieuwerts AM, Martens JW, Foekens JA, Sleijfer S.
Mol Cancer Ther. 2015 Mar;14(3):821-7.

Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial.
Dekker TJ, Charehbili A, Smit VT, Ten Dijke P, Meershoek-Klein Kranenbarg E, van de Velde CJH, Nortier JW, Tollenaar RA, Mesker WE, Kroep JR.
Mol Oncol. 2015 Jun;9(6):1120-8.

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Janssen LG, Charehbili A, Dijkgraaf EM, Smit VT, Kessels LW, van Bochove A, van Laarhoven HW, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van de Velde CJH, Putter H, Nortier JW, van der Hoeven JJ, Pijl H, Kroep JR.
Breast Cancer Res Treat. 2015 Jan;149(2):461-6.

BOOG 2010-02 / STOP & GO
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.
AKM Claessens,F LG Erdkamp, M Lopez-Yurda, JM Bouma, JM Rademaker-Lakhai, AH Honkoop, H de Graaf, V.C.G. Tjan-Heijnen, and M.E.M.M. Bos.
Acta Oncologica 2020

The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice.
Claessens AKM, Ibragimova KIE, Geurts SME, Bos MEMM, Erdkamp FLG, Tjan-Heijnen VCG.
Crit. Rev. Oncol. Hematol. 153:102988, 2020.

Schept pauze in chemokuur lucht?
F. Erdkamp en A. Claessens
Medische Oncologie 2020 nr 2

Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Claessens AKM, Bos MEMM, Lopez-Yurda M, Bouma JM, Rademaker-Lakhai JM, Honkoop AH, de Graaf H, van Druten E, van Warmerdam LJC, van der Sangen MJC, Tjan-Heijnen VCG, Erdkamp FLG Dutch Breast Cancer Research Group (BOOG).
Breast Cancer Res Treat. 2018 Nov;172(2):413-423. doi: 10.1007/s10549-018-4906-8. Epub 2018 Aug 18.

ESMO 2017(Poster 246-PD) gepresenteerd door Anouk Claessens

Beter doorbehandelen dan Stop & Go. Onderbreken van de behandeling geen zinvolle zaak
Jac Jansen, M. Bos
Bproefd BVN voorjaar 2013

BOOG 2010-03 / RAPCHEM
De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.

Sabine R de Wild, Linda de Munck, Janine M Simons, Janneke Verloop, Thijs van Dalen, Paula H M Elkhuizen, Ruud M A Houben, A Elise van Leeuwen, Sabine C Linn, Ruud M Pijnappel, Philip M P Poortmans, Luc J A Strobbe, Jelle Wesseling, Adri C Voogd, Liesbeth J Boersma.
Lancet Oncol . 2022 Sep;23(9):1201-1210. doi: 10.1016/S1470-2045(22)00482-X. Epub 2022 Aug 8.

Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03)
Liesbeth J Boersma , Janneke Verloop , Adri C Voogd, Paula H M Elkhuizen, Ruud Houben, A Elise van Leeuwen, Sabine Linn, Linda de Munck, Ruud Pijnappel, Luc Strobbe, Thijs van Dalen, Jelle Wesseling, Philip Poortmans
Radiother Oncol. 2020 Apr;145:201-208; DOI: 10.1016/j.radonc.2020.01.018

Radiotherapy After Primary CHEMotherapy (RAPCHEM): a prospective registration study
L. Boersma, P. Elkhuizen, R. Houben, E. van Leeuwen, S. Linn, L. de Munck, R. Pijnappel, L. Strobbe, T. van Dalen, J. Verloop, A. Voogd, J. Wesseling, P. Poortmans.
Abstract EBCC 2016

BOOG 2010-04 / D-care
De primaire analyse is op ASCO 2018 gepresenteerd
Coleman R, et al. Presented at: American Society of Clinical Oncology; June 1-5, 2018; Chicago, IL. USA.

BOOG 2010-05 / SUBMIT
SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation
Jetske Ruiterkamp1, Adri C Voogd2, Vivianne CG Tjan-Heijnen3, Koop Bosscha4, Yvette M van der Linden5, Emiel JTh Rutgers6, Epie Boven7, Maurice JC van der Sangen8, Miranda F Ernst39* and In collaboration with Dutch Breast Cancer Trialists' Group (BOOG)
BMC Surgery 2012, 12:5 doi:10.1186/1471-2482-12-5

The role of surgery in metastatic breast cancer
47 Suppl 3:S6-22. doi: 10.1016/S0959-8049(11)70142-3.
Ruiterkamp J, Ernst MF.
Eur J Cancer. 2011 Sep

Presence of symptoms and timing of surgery do not affect the prognosis of patients with primary metastatic breast cancer.
Ruiterkamp J, Voogd AC, Bosscha K, Roukema JA, Nieuwenhuijzen GA, Tjan-Heijnen VC, Ernst MF.
Eur J Surg Oncol. 2011 Oct;37(10):883-9. doi: 10.1016/j.ejso.2011.07.004. Epub 2011 Aug 16.

Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. A nation wide population-based study in The Netherlands.
Ruiterkamp J, Ernst MF, de Munck L, van der Heiden-van der Loo M, Bastiaannet E, van de Poll-Franse LV, Bosscha K, Tjan-Heijnen VC, Voogd AC.
Breast Cancer Res Treat. 2011 Jul;128(2):495-503. doi: 10.1007/s10549-011-1349-x. Epub 2011 Jan 15.

Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature.

Ruiterkamp J, Voogd AC, Bosscha K, Tjan-Heijnen VC, Ernst MF.
Breast Cancer Res Treat. 2010 Feb;120(1):9-16. doi: 10.1007/s10549-009-0670-0. Epub 2009 Dec 13. Review.

Jetske Ruiterkamp Thesis 'Surgery in metastatic breast cancer'

BOOG 2011-02 / APHINITY
Video: Targeted Oncology August 12, 2024
Paulo Tarantino, MD
Long-Term Pertuzumab Outcomes in HER2+ Breast Cancer: Insights from APHINITY 8-Year Data and NeoSphere Pooled Analysis

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
Sibylle Loibl, Jacek Jassem, Amir Sonnenblick, Damien Parlier, Eric Winer, Jonas Bergh, Richard D Gelber, Eleonora Restuccia, Young-Hyuck Im, Chiun-Sheng Huang, Florence Dalenc, Isabel Calvo, Marion Procter, Carmela Caballero, Emma Clark, Alice Raimbault, Robin McConnell, Estefania Monturus, Evandro de Azambuja, Henry L Gomez, Judith Bliss, Giuseppe Viale, Jose Bines, Martine Piccart; APHINITY Steering Committee and Investigators
J Clin Oncol 2024 Online ahead of print PMID: ***39259927 DOI****: 10.1200/JCO.23.02505*

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: sub-analysis of the APHINITY trial
De Azambuja E, Agostinetto E, Samy F, et al.
SABCS 2023 Abstract PS09-04
Cancer Research. 2024 ;84(9_Supplement) :PS09-04. doi: 10.1158/1538-7445.

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
E. de Azambuja, E. Agostinetto, M. Procter, D. Eiger, N. Pondé, S. Guillaume, D. Parlier, M. Lambertini, A. Desmet, C. Caballero, C. Aguila, G. Jerusalem, J. M. Walshe, E. Frank, J. Bines, S. Loibl, M. Piccart-Gebhart, M. S. Ewer, S. Dent, C. Plummer & T. Suter, on behalf of the APHINITY Steering Committee and Investigators
ESMO Open, 8(1), January 19, 2023. DOI: https://doi.org/10.1016/j.esmoop.2022.100772

Effect of young age at diagnosis on the clinical outcomes of women with HER2-positive early-stage breast cancer receiving adjuvant trastuzumab with or without pertuzumab in the APHINITY trial
Lambertini M, Fielding S, Loibl S, et al.
manuscript published in the Journal of the National Cancer Institute, 5 May 2022.

Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy
[published online ahead of print, 2022 May 5]. J Natl Cancer Inst. 2022;djac096. https://doi.org/10.1093/jnci/djac096

Regional timelines variation to initiate a multinational clinical trial: the Aphinity experience.
manuscript accepted at ecancermedicalscience.

Cardiotoxicity related to dual anti-HER2 blockade in the APHINITY Trial, manuscript under peer-review. *ASCO abstract 2023*

Cardiotoxicity related to dual anti-HER2 blockade in the APHINITY Trial
abstract presented at ASCO 2021, manuscript under peer-review.

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
Richard D. Gelber, Xin V. Wang, Bernard F. Cole, Sibylle Loibl, Martine Piccart-Gebhart, on behalf of the APHINITY Steering Committee and Investigators
Eur Journal of Cancer| VOLUME 166, P219-228, MAY 01, 2022

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Martine Piccart et al for the APHINITY Steering Committee and Investigators
J Clin Oncol, 4 Feb 2021 ; https://doi.org/10.1200/JCO.20.01204

BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial
Ian Krop et al, *SABCS 2020 PD3-01*

6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A STEPP analysis of the APHINITY (BIG 4-11) trial
Richard D. Gelber et al, *SABCS 2020 PS10-01*

Timelines to initiate an adjuvant phase III trial across the globe: A sub-analysis of the APHINITY trial
Maria Alice Franzoi et al, *SABCS 2020 PS7-21*

Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis
Zambelli A, Pappagallo G, Marchetti P.
J Comp Eff Res. 2020 Feb 14. doi: 10.2217/cer-2019-0168.

Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
Kirschbrown WP, Kågedal M1, Wang B1, Lindbom L2, Knott A3, Mack R3, Monemi S1, Nijem I1, Girish S1, Freeman C4, Fumagalli D5, McConnell R6, Jerusalem G7, Twelves C8, Baselga J9, von Minckwitz G10, Bines J11, Garg A12.
Cancer Chemother Pharmacol. 2019 Apr 11. doi: 10.1007/s00280-019-03826-1

Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer
Luo Y, Li W, Jiang Z, Zhang Q, Wang L, Mao Y, Tjan-Heijnen VCG, Im SA, McConnell R, Bejarano S, Fumagalli D, Bines J, Wang B, Garg A, Kirschbrown WP, Xu B
Anticancer Drugs. 2019 Sep;30(8):866-872. doi: 10.1097/CAD.0000000000000808

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, Van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber R, Piccart M, Mobus V, de Azambuja E, on behalf of the APHINITY Steering Committee and Investigators
Clin Breast Cancer. 2019 Sep 5 doi: 10.1016/j.clbc.2019.06.016.

Adjuvant, Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J;
N Engl J Med. 2017 Jul 13;377(2):122-131

Presentatie van de eerste analyse van de APHINITY studie heeft op de ASCO 2017 plaatsgevonden
J Clin Oncol 35, 2017 (suppl; abstr LBA500)

Helpt extra middel bij HER2-positieve borstkanker?
Jac Jansen, Maaike de Boer
B-proefd BVN 2014 nr 10

BOOG 2012-01 / BALLET
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P.
Ann Oncol. 2016 Sep;27(9):1719-25. doi: 10.1093/annonc/mdw249. Epub 2016 Jun 29

Everolimus in combination with exemestane in hormone receptor-positive locally advanced or metastatic breast cancer (BC) patients progressing on prior non-steroidal AI (NSAIs): Ballet study (CRAD001YIC04)
Guy Jerusalem1, Gabriella Mariani2, Eva M Ciruelos3, Miguel Martin4, Vivianne CG Tjan-Heijnen5, Patrick Neven6, Joaquin Gavila Gregori7, Andrea Michelotti8, Filippo Montemurro9, Istvan Lang10, Josef Mardiak11, Bjoem Naume12, Maura Camozzi13, Katia Lorizzo13, Dariusz Brenski13 and Pierfranco Conte14. 1CHU Sart Tilman Liege and Liege University, Liege, Belgium; 2Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy; 3University Hospital 12 de Octubre, Madrid, Spain; 4Hospital General Universitario Gregorio Marañón, Madrid, Spain; 5Maastricht University Medical Centre, Maastricht, Netherlands; 6KU Leuven and University Hospital Leuven, Leuven, Belgium; 7Fundacion Instituto Valenciano de Oncologia, Valencia, Spain; 8Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Pisa, Italy; 9Fondazione del Piemonte per l'Oncologia, Institute of Candiolo Cancer Center (IRCCs), Candiolo (Torino), Italy; 10National Institute of Oncology, Budapest, Hungary; 11National Cancer Institute, Bratislava, Slovakia (Slovak Republic); 12Oslo University Hospital and Norwa and K.G. Jebsen Center for Breast Cancer
Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway; 13Novartis Farma S.p.A., Origgio/VA, Italy and 14Istituto Oncologico Veneto IRCCS and Università di Padova, Padova, Italy.
SABCS 2014, publication number: P5-19-02

BOOG 2012-02 / SafeHer

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

J. Gligorov , B. Ataseven , M. Verrill , M. De Laurentiis , K.H. Jung e, H.A. Azim , N. Al-Sakaff , S. Lauer , M. Shing i , X. Pivot on behalf of the SafeHer Study Group.
EJC 82(2017)237-246

SafeHer Phase III study primary analysis: Safety of subcutaneous trastuzumab plus chemotherapy for early breast cancer

EBCC 2016 abstract number: 326

SafeHer Phase III study primary analysis: Safety of subcutaneous trastuzumab plus chemotherapy for early breast cancer

J. Gligorov(1), B. Ataseven(2), M. Verrill(3), M. De Laurentiis(4), K.H. Jung(5), H.A. Azim(6), N. Al-Sakaff(7), S. Lauer(8), M. Shing(9), X. Pivot(10)
EBCC 2016 poster presentation 343

Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses

Poster presented at the European Cancer Congress 2015, September 25–29 2015, Vienna, Austria

BOOG 2012-03 / TRAIN-2

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade

Gabe Sonke, Marte Liefaard, Anna van der Voort, Maartje van Seijen, Bram Thijssen, Joyce Sanders, Shiva Vonk, Lorenza Mittempergher, Rajit Bhaskaran, Linda de Munck, Elise van Leeuwen-Stok, Roberto Salgado, Hugo Horlings, and Esther Lips
NPJ Breast Cancer 10.1 (2024): 29.

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

M. C. Liefaard, A. van der Voort, M. S. van Ramshorst, J. Sanders, S. Vonk, H. M. Horlings, S. Siesling, L. de Munck, A. E. van Leeuwen, M. Kleijn, L. Mittempergher, M. M. Kuilman, A. M. Glas, J. Wesseling, E. H. Lips & G. S. Sonke
Breast Cancer Research volume 25, Article number: 71 (2023)

Prognostic value of tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade: a TRAIN-2 sub study

M.C. Liefaard, A. van der Voort, M. van Seijen, J. Sanders, S. Vonk, L. de Munck, A.E. van Leeuwen-Stok, H.M. Horlings, R. Salgado, E.H. Lips, G.S. Sonke
Annuals of Oncology, 2022; 33(S7); S606. DOI: https://doi.org/10.1016/j.annonc.2022.07.180

Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.

Anna van der Voort, Mette S. van Ramshorst, Erik D. van Werkhoven, Ingrid A. Mandjes, Inge Kemper, Annelie J. Vulink, Irma M. Oving, Aafke H. Honkoop, Lidwine W. Tick, Agnes J. van de Wouw, Caroline M. Mandigers, Laurence J. C. van Warmerdam, Jelle Wesseling, Marie-Jeanne

T.F.D Vrancken Peeters, Sabine C. Linn, Gabe S. Sonke, and on behalf of the Dutch Breast Cancer Research Group (BOOG)
JAMA Oncol. 2021;7(7):978-984. doi:10.1001/jamaoncol.2021.1371 *en: ASCO 2020 abstract number 501*

Effect of pertuzumab plus neoadjuvant trastuzumab-based chemotherapy in early-stage HER2-positive breast cancer according to BluePrint molecularly defined breast cancer subtypes
SABCS 2021 abstract PD15-07 Liefaard MC

Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.
Anna van der Voort, Mette S. van Ramshorst, Erik D. van Werkhoven, Ingrid A. Mandjes, Inge Kemper, Annelie J. Vulink, Irma M. Oving, Aafke H. Honkoop, Lidwine W. Tick, Agnes J. van de Wouw, Caroline M. Mandigers, Laurence J. C. van Warmerdam, Jelle Wesseling, Marie-Jeanne T.F.D Vrancken Peeters, Sabine C. Linn, Gabe S. Sonke, and on behalf of the Dutch Breast Cancer Group (BOOG);
ASCO 2020 abstract number 501

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicenter, open-label, randomized, phase 3 trial.
Van Ramshorst MS, van der Voort A, van Werkhoven ED, Manjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MJTFD, Linn SC, Sonke GS; Dutch Breast Canser Research Group (BOOG).
Lancet Oncol 2018; 19: 1543-1698

Fine-tuning chemotherapy in the era of dual HER2 targeting
Editorial Lancet Oncol 2018

A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer: the TRAIN-2 study (BOOG 2012-03)
Van Ramshorst MS, van Werkhoven ED, Manjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, Wesseling J, Vrancken Peeters MJTFD, Linn SC, Sonke GS;
ASCO 2017 abstract number 507

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenburg CH, Stouthard JM, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG). *Breast. 2016;29:153-9.*

Safety analyses of the first 110 patients treated with dual HER2-blockade in the TRAIN-2 study
Mette S van Ramshorst[1*], Erik van Werkhoven[2], Aafke H Honkoop[3], Vincent O Dezentjé[4], Irma M Oving[5], Ingrid AM Mandjes[2], Inge Kemper[1], Jacqueline M Stouthard[1], Sjoerd Rodenhuis[1], Sabine

C Linn[1], Gabe S Sonke[1*]
EBCC 2016 abstract number 343

BOOG 2013-01 / TRIPLE-B,
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for **Metastatic Triple-Negative Breast Cancer (BOOG 2013-01)**
Annelot G.J. van Rossuma Ingrid A.M. Mandjesb Erik van Werkhovenc Harm van Tinterenc A. Elise van Leeuwen-Stokd Petra Nederlofe Johanna E.A. Portieljef, g Robbert J. van Alphenh Els Plattei Daan van den Broeki Alwin Huitemaj Marleen Kokk, l Sabine C. Linna, l, m Hendrika M. Oosterkampn on behalf of the Triple-B trialists' group
Breast Care 9 DOI: 10.1159/000512200

Triple-negatieve borstkanker
Sabine Linn, Gabe Sonke
B-proefd BVN 2013 midwinter nr 9

BOOG 2013-02 / PROS MALE BC
Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG).
Schröder CP, van Leeuwen-Stok E, Cardoso F, Linderholm B, Poncet C, Wolff AC, Bjelic-Radisic V, Werutsky G, Abreu MH, Bozovic-Spasojevic I, den Hoed I, Honkoop AH, Los M, Leone JP, Russell NS, Smilde TJ, van der Velden AWG, Van Poznak C, Vleugel MM, Yung RL, Coens C, Giordano SH, Ruddy KJ.
Oncologist. 2023 Oct 3; 28(10):e877-e883. doi: 10.1093/oncolo/oyad152

NANOSTRING: Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. Bayani J, Poncet C, Crozier C, Neven A, Piper T, Cunningham C, Sobol M, Aebi S, Benstead K, Bogler O, Dal Lago L, Fraser J, Hilbers F, Hedenfalk I, Korde L, Linderholm B, Martens J, Middleton L, Murray M, Kelly C, Nilsson C, Nowaczyk M, Peeters S, Peric A, Porter P, Schröder C, Rubio IT, Ruddy KJ, van Asperen C, Van Den Weyngaert D, van Deurzen C, van Leeuwen-Stok E, Vermeij J, Winer E, Giordano SH, Cardoso F, Bartlett JMS.
NPJ Breast Cancer. 2021 Jul 26;7(1):98.

Loss of Y-Chromosome during Male Breast Carcinogenesis. Cancers.
Agahozo MC, Timmermans MAM, Sleddens HFBM, Foekens R, Trapman-Jansen AMAC, Schröder CP, van Leeuwen-Stok E, Martens JWM, N M Dinjens W, van Deurzen CHM.
Cancers. 2020;12(3).

High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer
Qiu SQ, van Rooijen J, Nienhuis HH et al.
Breast Cancer Res. 2020 Mar 18;22(1):30. doi: 10.1186/s13058-020-01266-x.

Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast. J Clin Pathol.
Vermeulen MA, van Deurzen CH, Schroder CP, Martens JW, van Diest PJ.
J Clin Pathol. 2019 Oct 25. pii: jclinpath-2019-206116. doi: 10.1136/jclinpath-2019-206116.

Profiling Male Breast Cancers using the Oncomine Comprehenisve Assay.*(M. Spears)*
Status: Samples were analyzed. The abstract with bioinformatics results has been presented at San Antonio Breast Cancer Symposium 2019. Manuscript is under preparation.

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litière S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH. *Ann Oncol. 2018; 29:405-417.*

Male breast cancer RNA sequencing. *(J. Martens)*
Status: Analyses of first 73 patients completed, presented at SABCS 2017 (poster spotlight). Additional samples were analyzed. Further analysis are ongoing.

Als man behandeld, gráág! Pink Ribbon-project. Optimale voorlichting en zorg voor mannen met borstkanker
Paul Peijenerburg
BVN 2016 nr 18

BOOG 2013-03 / PERNETTA
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H; Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group.*JAMA Oncol. 2023 Aug 10:e232909. doi: 10.1001/jamaoncol.2023.2909.*

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)\' https://www.scienceopen.com/document?vid=c18084ed-0ac8-486d-8264-9f46a18c6575

Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)
J. Huober, K. Ribi, P. Weder, B. Thürlimann, E. Boven, H. Bonnefoi
Annals of Oncology:https://doi.org/10.1093/annonc/mdz100.001

ASCO post 2019: ESMO Breast Cancer 2019: PERNETTA Trial Examines Treatment De-escalation in Women with HER2-Positive Breast Cancer https://ascopost.com/News/59995
Huober J, et al. Presented at: European Society for Medical Oncology (ESMO) Congress, Munich, Germany, October 19-23, 2018.

BOOG 2013-04 / DIRECT
IGF1 and Insulin Receptor Single Nucleotide Variants Associated with Response in HER2-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without a Fasting Mimicking Diet (BOOG 2013-04 DIRECT Trial).
de Gruil N, Böhringer S, de Groot S, Pijl H, Kroep JR, Swen JJ.

Cancers (Basel). 2023 Dec 17;15(24):5872.

Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer.
Hagenaars SC, de Groot S, Cohen D, Dekker TJA, Charehbili A, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Pijl H, Putter H, Tollenaar RAEM, Kroep JR, Mesker WE; Dutch Breast Cancer Research Group (BOOG).
Int J Cancer. 2021 May 27.

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial.
Lugtenberg RT, de Groot S, Kaptein AA, Fischer MJ, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Cohen D, de Graaf H, Heijns JB, Portielje JEA, van de Wouw AJ, Imholz ALT, Kessels LW, Vrijaldenhoven S, Baars A, Fiocco M, van der Hoeven JJM, Gelderblom H, Longo VD, Pijl H, Kroep JR; Dutch Breast Cancer Research Group (BOOG).
Breast Cancer Res Treat. 2020 Nov 11.

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial.
de Groot S, Lugtenberg RT, Cohen D, Welters MJP, Ehsan I, Vreeswijk MPG, Smit VTHBM, de Graaf H, Heijns JB, Portielje JEA, van de Wouw AJ, Imholz ALT, Kessels LW, Vrijaldenhoven S, Baars A, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van der Hoeven JJM, Nortier JWR, Longo VD, Pijl H, Kroep JR; Dutch Breast Cancer Research Group (BOOG).
Nat Commun. 2020 Jun 23;11(1):3083.

DIetary REstriction as an adjunct to neoadjuvant ChemoTherapy for HER2-negative breast cancer: *Final results from the DIRECT trial (BOOG 2013-04).*
S. de Groot, R.T. Lugtenberg, M.J.P. Welters, I. Ehsan, M.P.G. Vreeswijk, D. Cohen, V.T.H.B.M. Smit, H. de Graaf, J. B. Heijns, J.E.A. Portielje, A.J. van de Wouw, A.L.T. Imholz, L.W. Kessels, S. Vrijaldenhoven, A. Baars, E. Meershoek-Klein Kranenbarg, M. Duijm-de Carpentier, H. Putter, V.D. Longo, J.J.M. van der Hoeven, J.W.R. Nortier, H. Pijl, J.R. Kroep1on behalf of the Dutch Breast Cancer Research Group (BOOG)
SABCS 2018 Poster presentation(P1-15-20)

The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study.
de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, Houtsma D, Putter H, van der Hoeven JJ, Nortier JW, Pijl H, Kroep JR.
BMC Cancer. 2015 Oct 5;15:652.

BOOG 2013-06 / BIOMARKER EVEROLIMUS
PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane
Dinja T. Kruger, Mark Opdam, Vincent van der Noort, Joyce Sanders, Michiel Nieuwenhuis, Bart de Valk, Karin J. Beelen, Sabine C. Linn, and Epie Boven
J Cancer Res Clin Oncol. 2020; 146(11): 3013–3023.
Published online 2020 Jun 21. doi: 10.1007/s00432-020-03291-x

PI3K-Akt-mTOR pathway analysis to obtain further insight in the efficacy of everolimus in combination with exemestane in metastatic, ER-positive breast cancer: A Dutch breast cancer research group (BOOG) study

Dinja T Kruger1, Karin Beelen2, Connie R Jimenez1, Maurice PHM Jansen3, Stefan Sleijfer3, Sabine C Linn2 and Epie Boven1..
SABCS 2014, publication mumber: OT1-1-02

De Everolimus Biomarker Studie: analyse van de PI3K-Akt-mTOR route om meer inzicht te verkrijgen in de effectiviteit van everolimus in combinatie met exemestaan bij gemetastaseerd mammacarcinoom - Een studie van de Borstkanker Onderzoek Groep (BOOG) Nederland
Kruger DT, Linn SC, Beelen K, Sleijfer S, Jansen MPHM, Jimenez CR, Boven E.
Ned Tijdschr Oncol 2014;11:250-254

Biomarker Study Everolimus, een studie van de Borstkanker Onderzoek Groep Nederland
Kruger DT, Beelen K, Sleijfer S, Jansen MPHM, Jimenez CR, Linn SC, Boven E.
Kanker Breed 2014;6:23-25

BOOG 2013-08 / Lumpectomie
Three-year patient-reported outcomes of the BOOG 2013-08 trial evaluating the omission of sentinel lymph node biopsy in early-stage breast cancer patients treated with breast-conserving surgery—impact of personality traits on health-related quality of life: randomized clinical trial
Veerle M. Wintraecken, Lori M. van Roozendaal, Janine M. Simons, Jolanda de Vries, Sander M. J. van Kuijk, Marissa L. G. Vane,Thijs van Dalen, Helena Sackey, Jos A. van der Hage,Luc J. A. Strobbe, Sabine C. Linn, Marc B. I. Lobbes, Philip M. P. Poortmans, Vivianne C. G. Tjan-Heijnen, Koen K. B. T. van de Vijver, Helen H. Westenberg, Carmen D. Dirksen , Johan H. W. de Wilt, Liesbeth J. Boersma, Marjolein L. Smidt
(2025) British Journal of Surgery, accepted january 2025

Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial
V M Wintraecken 1, L J Boersma 2, L M van Roozendaal 3, J de Vries 4, S M J van Kuijk 5, M L G Vane 6, T van Dalen 7, J A van der Hage 8, L J A Strobbe 9, S C Linn 10, M B I Lobbes 11, P M P Poortmans 12, V C G Tjan-Heijnen 13, K K B T van de Vijver 14, A H Westenberg 15, J H W de Wilt 16, M L Smidt 6, J M Simons 17; BOOG 2013-08 group
Radiother Oncol. 2024 Feb:191:110069. doi: 10.1016/j.radonc.2023.110069. Epub 2023 Dec 21

A descriptive systematic review of the relationship between personality traits and quality of life of women with non-metastatic breast cancer
Veerle Marieke Wintraecken, Sophie Vulik, Sabine de Wild, Carmen Dirksen, Linetta B Koppert, Jolanda de Vries, Marjolein L Smidt Affiliations expand
BMC Cancer 2022 Apr 19;22(1):426. doi: 10.1186/s12885-022-09408-4.

Conditional local recurrence risk: the effect of event-free years in different subtypes of breast cancer
Moossdorff M, Vane MLG, van Nijnatten TJA, van Maaren MC, Goorts B, Heuts EM, Strobbe LJA, Smidt ML.
Breast Cancer Res Treat. 2021 Apr;186(3):863-870. doi: 10.1007/s10549-020-06040-3. Epub 2021 Mar 10. PMID: 33689058 ***Free PMC article.***

Women Could Avoid Axillary Lymph Node Dissection by Choosing Breast-Conserving Therapy Instead of Mastectomy

Vane MLG, Hunter-Squires J, Kim S, Smidt ML, Giuliano AE.
Ann Surg Oncol. 2021 May;28(5):2522-2528. doi: 10.1245/s10434-021-09674-9. Epub 2021 Feb 14.
PMID: 33586070

Conditional regional recurrence risk: The effect of event-free years in different subtypes of breast cancer.
Vane MLG, Moossdorff M, van Maaren MC, van Kuijk SMJ, van Nijnatten TJA, van Roozendaal LM, Boerma EG, de WIlt JHW, Smidt ML.Vane MLG, et al.
Eur J Surg Oncol. 2020 Nov 27:S0748-7983(20)31018-0. doi: 10.1016/j.ejso.2020.11.122. Online ahead of print.Eur J Surg Oncol. 2020. PMID: 33349525

Does the subtype of breast cancer affect the diagnostic performance of axillary ultrasound for nodal staging in breast cancer patients?
Vane MLG, van Nijnatten TJA, Nelemans PJ, Lobbes MBI, van Roozendaal LM, Kooreman LFS, Keymeulen KBMI, Smidt ML, Schipper RJ. Eur J Surg
Oncol. 2019 Jan 14. pii: S0748-7983(19)30035-6

Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?
Vane MLG, Willemsen MA, van Roozendaal LM, van Kuijk SMJ, Kooreman LFS, Siesling S, de Wilt HHW, Smidt ML.
Breast Cancer Res Treat. 2019 Jan 4. doi: 10.1007/s10549-018-05074-y

Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08).
van Roozendaal LM, Vane MLG, van Dalen T, van der Hage JA, Strobbe LJA, Boersma LJ, Linn SC, Lobbes MBI, Poortmans PMP, Tjan-Heijnen VCG, Van de Vijver KKBT, de Vries J, Westenberg AH, Kessels AGH, de Wilt JHW, Smidt ML.
BMC Cancer. 2017 Jul 1;17(1):459. doi: 10.1186/s12885-017-3443-x. PubMed PMID: 28668073; PubMed Central PMCID:PMC5494134.

Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.
van Roozendaal LM, Goorts B, Klinkert M, Keymeulen KBMI, De Vries B, Strobbe LJA, Wauters CAP, van Riet YE, Degreef E, Rutgers EJT, Wesseling J, Smidt ML.
Breast Cancer Res Treat. 2016 Apr;156(3):517-525. doi:10.1007/s10549-016-3783-2. Epub 2016 Apr 15. PubMed PMID: 27083179; PubMed Central PMCID: PMC4837213

Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study.
van Roozendaal LM, Smit LHM, Duijsens GHNM, de Vries B, Siesling S, Lobbes MBI, de Boer M, de Wilt JHW, Smidt ML.
Breast Cancer Res Treat. 2016 Apr;156(3):465-472. doi: 10.1007/s10549-016-3757-4. Epub 2016 Mar 25.
PubMed PMID: 27013474; PubMed Central PMCID: PMC4837212

The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).
van Roozendaal LM, de Wilt JH, van Dalen T, van der Hage JA, Strobbe LJ, Boersma LJ, Linn SC, Lobbes MB, Poortmans PM, Tjan-Heijnen VC, Van de Vijver KK, de Vries J, Westenberg AH, Kessels AG, Smidt ML.
BMC Cancer. 2015 Sep 3;15:610. doi: 10.1186/s12885-015-1613-2. PubMed PMID: 26335105; PubMed Central PMCID: PMC4559064.

The changing role of axillary treatment in breast cancer: Who will remain at risk for developing arm morbidity in the future?
Lopez Penha TR, van Roozendaal LM, Smidt ML, Boersma LJ, von Meyenfeldt MF, Voogd AC, Heuts EM.
Breast. 2015 Oct;24(5):543-7. doi: 10.1016/j.breast.2015.04.008. Epub 2015 Jun 6. Review. PubMed PMID: 26051795.

Three-Dimensional Breast Radiotherapy and the Elective Radiation Dose at the Sentinel Lymph Node Site in Breast Cancer.
van Roozendaal LM, Schipper RJ, Smit LH, Brans BT, Beets-Tan RG, Lobbes MB, Boersma LJ, Smidt ML.
Ann Surg Oncol. 2015 Nov;22(12):3824-30. doi: 10.1245/s10434-015-4413-7. Epub 2015 Feb 24. PubMed PMID: 25707492; PubMed Central PMCID: PMC4595528.

Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research.
Moossdorff M, van Roozendaal LM, Strobbe LJ, Aebi S, Cameron DA, Dixon JM, Giuliano AE, Haffty BG, Hickey BE, Hudis CA, Klimberg VS, Koczwara B, Kühn T, Lippman ME, Lucci A, Piccart M, Smith BD, Tjan-Heijnen VC, van de Velde CJ, Van Zee KJ, Vermorken JB, Viale G, Voogd AC, Wapnir IL, White JR, Smidt ML.
J Natl Cancer Inst. 2014 Nov 7;106(12). pii: dju288. doi: 10.1093/jnci/dju288. Print 2014 Dec. PubMed PMID: 25381395; PubMed Central PMCID: PMC4357796.

The impact of the pathological lymph node status on adjuvant systemic treatment recommendations in clinically node negative breast cancer patients.
van Roozendaal LM, Schipper RJ, Van de Vijver KK, Haekens CM, Lobbes MB, Tjan-Heijnen VC, de Boer M, Smidt ML.
Breast Cancer Res Treat. 2014 Feb;143(3):469-76. doi:10.1007/s10549-013-2822-5. Epub 2014 Jan 4. PubMed PMID: 24390150.

Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value? Schipper RJ, van Roozendaal LM, de Vries B, Pijnappel RM, Beets-Tan RG, Lobbes MB, Smidt ML.
Breast. 2013 Dec;22(6):1108-13. doi: 10.1016/j.breast.2013.09.002. Epub 2013 Oct 2. PubMed PMID: 24095611.

BOOG 2014-01 / MONALEESA-2
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials
Hart et al.

Eur J Cancer 217 (2025) 115225

Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Prat et al
Clinical Cancer Research 2024

Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
André, F. et al.
Ann of Oncol 2023, Vol.34; iss.11; 1003-1014

Efficacy, safety, and quality of life with ribociclib + endocrine therapy in elderly patients with HR+/HER2– advanced breast cancer across the MONALEESA-2, -3, and -7 trials
Hart et al
SABCS 2023; #PS02-01

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison
Rugo et al
Ther Adv Med Oncol 2023

Cost-effectiveness of ribociclib versus Palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2– advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2
Cameron et al
JME 2023

Efficacy and safety of first line ribociclib + letrozole in patients with de novo metastatic disease and late recurrence from (neo)adjuvant therapy in MONALEESA 2
Joyce O'Shaughnessy et al 196P
ESMO Breast 2023

Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
André et al P5-02-14
SABCS 2022

Pooled gene expression analysis and association with treatment response in patients with HR+/HER2–advanced breast cancer in the MONALEESA-2, -3, and -7 trials
Bardia et al PD17-08
SABCS 2022

Pooled analysis of post-progression treatments after first-line ribociclib + endocrine therapy in patients with HR+/HER2– advanced breast cancer in the MONALEESA-2, -3, and -7 studies
Hamilton et al P4-01-42
SABCS 2022

Impact of ribociclib dose modifications on overall survival in patients with HR+/HER2– advanced breast cancer in MONALEESA-2. ASCO 2022 poster Hart (#1017)

Pooled exploratory analysis of survival in patients (pts) with HR+/HER2– advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib(RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials ESMO 2022 poster Yardley (#205P)

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
Gabriel N. Hortobagyi, M.D., Salomon M. Stemmer, M.D., Howard A. Burris, M.D., Yoon-Sim Yap, M.D., Gabe S. Sonke, M.D., Ph.D., Lowell Hart, M.D., Mario Campone, M.D., Ph.D., Katarina Petrakova, M.D., Ph.D., Eric P. Winer, M.D., Wolfgang Janni, M.D., Ph.D., Pierfranco Conte, M.D., Ph.D., David A. Cameron, M.D., Fabrice André, M.D., Ph.D., Carlos L. Arteaga, M.D., Juan P. Zarate, M.D., Arunava Chakravartty, Ph.D., Tetiana Taran, M.D., Fabienne Le Gac, Ph.D., Pharm.D., Paolo Serra, M.Sc., and Joyce O'Shaughnessy, M.D
N Engl J Med 2022; 386:942-950 DOI: 10.1056/NEJMoa2114663

Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2– advanced breast cancer; *SABCS 2021 abstract GS2-00 Carey*

Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2– breast cancer
SABCS 2021 abstract PD2-05 Prat

Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies
SABCS 2021 abstract GS2-01 O'Shaughnessy

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, Villanueva C, Jakobsen E, Alba E, Wist E, Favret AM, Bachelot T, Hegg R, Wheatley-Price P, Souami F, Sutradhar S, Miller M, Germa C, Burris HA.
https://www.ncbi.nlm.nih.gov/pubmed/29058175 Breast Cancer Res Treat. 2018 Feb;167(3):659-669

Updated results from MONALEESA-2, a phase III trial of first line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J.
Ann Oncol. 2018 Jul 1;29(7):1541-1547

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial
O'Shaughnessy J, Petrakova K, Sonke GS, Conte P, Arteaga CL, Cameron DA, Hart LL, Villanueva C, Jakobsen E, Beck JT, Lindquist D, Souami F, Mondal S, Germa C, Hortobagyi GN.
Breast Cancer Res Treat. 2018 Feb;168(1):127-134

Ribociclib plus letrozole versus letrozole alone in patients with denovo HR+, HER2– advanced breast cancer in the randomized MONALEESA-2 trial
Joyce O'Shaughnessy, Katarina Petrakova, Gabe S. Sonke, Pierfranco Conte, Carlos L. Arteaga, David A. Cameron, Lowell L. Hart, Cristian Villanueva, Erik Jakobsen, Joseph T. Beck, Deborah Lindquist, Farida Souami, Shoubhik Mondal,Caroline Germa1,Gabriel N. Hortobagyi

Breast Cancer Research and Treatment, 18 September 2017

First-line Ribociclib + Letrozole in Patients With De Novo HR+, HER2– Advanced Breast Cancer: A Subgroup Analysis of the MONALEESA-2 Trial. Publication number P4-22-05. Joyce O'Shaughnessy, Katarina Petrakova, Gabe S. Sonke, Fabrice André, Pierfranco Conte, Carlos L. Arteaga, David A. Cameron, Lowell L. Hart, Cristian Villanueva, Erik Jakobsen, Deborah Lindquist, Farida Souami, Xiaodong Li, Caroline Germa, Samit Hirawat, Gabriel N. Hortobagyi. *Poster presented at SABCS, December 2016, San Antonio.*

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J.
N Engl J Med. 2016 Oct 7.

BOOG 2014-02 / BRAVO
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. Turner NC, Balmaña J, Poncet C, Goulioti T, Tryfonidis K, Honkoop AH, Zoppoli G, Razis E, Johannsson OT, Colleoni M, Tutt AN, Audeh W, Ignatiadis M, Mailliez A, Trédan O, Musolino A, Vuylsteke P, Juan-Fita MJ, Macpherson IRJ, Kaufman B, Manso L, Goldstein LJ, Ellard SL, Láng I, Jen KY, Adam V, Litière S, Erban J, Cameron DA; BRAVO Steering Committee and the BRAVO investigators.*Clin Cancer Res. 2021 Jul 22.*

BOOG 2014-03 / OLYMPIA
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer,
Ganz PA, Bandos H, Španić T, et al.
Journal of Clinical Oncology. Published online February 2024:JCO.23.01214.
*doi:*10.1200/JCO.23.01214

Abstract SABCS 2024 updated analysis reports the results of the third pre-specified IA with median follow-up (MFU) of 6.1 years (maximum, 9.6 years). GS1-09: OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2- negative primary breast cancer: Judy Garber, David Cameron, Christine Campbell, Greg Yothers, Maria Taboada, Sarra ElAbed, Priya Rastogi, Vicki Paterson, Jinyu Kang, Stephanie Zafonte, Liu Xiaochun, Giuseppe Viale, Tanja Spanic, Rita Schmutzler, Martine Piccart, Sibylle Loibl, Barbro Linderholm, Sunil R. Lakhani, Larissa Korde, Michael Gnant, Karen Gelmon, Sue Friedman, Tanner Freeman, Susan M. Domchek, Gursel Aktan, Richard D. Gelber, Charles E. Geyer, Jr., Andrew N.J. Tutt

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
Yamauchi, H. et al.
Breast Cancer. 2023;30(4):596-605. doi:10.1007/s12282-023-01451-8

Patient-reported Outcomes in OlympiA: A Phase III, Multicenter, Randomized, Placebo-controlled Trial of Adjuvant Olaparib in Patients with gBRCA1/2 Mutations and High-risk HER2-negative Early Breast Cancer
Ganz, et al.
Journal of Clinical Oncology. 2024 feb 1. doi: 10.1200/JCO.23.01214

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
C E Geyer Jr, J E Garber , R D Gelber, G Yothers, M Taboada, L Ross, P Rastogi, K Cui, A Arahmani , G Aktan, A C Armstrong, M Arnedos, J Balmaña, J Bergh, J Bliss, S Delaloge, S M Domchek, A Eisen, F Elsafy, L E Fein, A Fielding, J M Ford, S Friedman, K A Gelmon, L Gianni, M Gnant, S J Hollingsworth, S-A Im, A Jager, Ó Þ Jóhannsson, S R Lakhani, W Janni, B Linderholm, T-W Liu, N Loman, L Korde, S Loibl, P C Lucas, F Marmé, E Martinez de Dueñas, R McConnell, K-A Phillips, M Piccart, G Rossi, R Schmutzler, E Senkus, Z Shao, P Sharma, C F Singer, T Španić, E Stickeler, M Toi, T A Traina, G Viale, G Zoppoli, Y H Park, R Yerushalmi, H Yang, D Pang, K H Jung 56, A Mailliez 57, Z Fan 58, I Tennevet 59, J Zhang 60, T Nagy 61, G S Sonke 62, Q Sun 63, M Parton 64, M A Colleoni 65, M Schmidt 66, A M Brufsky 1, W Razaq 67, B Kaufman 68, D Cameron 69, C Campbell 70, A N J Tutt 71; OlympiA Clinical Trial Steering Committee and Investigators
PMID: ***36228963*** *DOI: 10.1016/j.annonc.2022.09.159*

Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer
SABCS abstract 2021 GS4-09 Ganz PA

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. Andrew Tutt, Judy Ellen Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmana Gelpi, Karen A. Gelmon, Nigel Baker, Amal Arahmani, Elzbieta Senkus-Konefka, Eleanor Mc Fadden, Vassiliki Karantza, Sunil R. Lakhani, Greg Yothers, Christine Campbell, Charles E. Geyer *Late breaking oral presentation at ASCO Annual Meeting, June 2021; DOI: 10.1200/JCO.2021.39.15_suppl.LBA1 Journal of Clinical Oncology 39, no. 18_suppl*

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. Andrew N.J. Tutt, Judy E. Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña, Susan M. Domchek, Karen A. Gelmon, Simon J. Hollingsworth, Larissa A. Korde, Barbro Linderholm, Hanna Bandos, Elżbieta Senkus, Jennifer M. Suga, Zhimin Shao, Andrew W. Pippas, Zbigniew Nowecki, Tomasz Huzarski, Patricia A. Ganz, Peter C. Lucas, Nigel Baker, Sibylle Loibl, Robin McConnell, Martine Piccart, Rita Schmutzler, Guenther G. Steger, Joseph P. Costantino, Amal Arahmani, Norman Wolmark, Eleanor McFadden, Vassiliki Karantza, Sunil R. Lakhani, Greg Yothers, Christine Campbell, and Charles E. Geyer, for the OlympiA Clinical Trial Steering Committee and Investigators. *Published in New England Journal of Medicine, June 2021 (https://doi.org/10.1056/nejmoa2105215).*

OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germline *BRCA1/2* mutation (gBRCAm)
Mark Robson, Andrew Tutt, Judith Balmaña, Bella Kaufman, Judy Garber, Charles Geyer, James Ford, Priyanka Sharma, Mary Stuart, Helen Mann and Peter A Fasching.

SABCS 2020, publication number: OT1-1-04

BOOG 2014-04 / LORD
DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCIS
Engelhart et al.
Breast. 2024-10 https://pubmed.ncbi.nlm.nih.gov/38970983/

Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ
Marjanka K Schmidt, Esther H Lips, Renée SJM Schmitz, Ellen Verschuur, Jelle Wesseling.
BMJ 2024; 384

Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study
Renée S J M Schmitz, Alexandra W van den Belt-Dusebout,,Karen Clements, Yi Ren,Chiara Cresta, Jasmine Timbres,Yat-Hee Liu, Danalyn Byng,Thomas Lynch,Brian A Menegaz, Deborah Collyar, Terry Hyslop, Samantha Thomas, Jason K Love,Michael Schaapveld , Proteeti Bhattacharjee, Marc D Ryser, Elinor Sawyer, E Shelley Hwang, Alastair Thompson, Jelle Wesseling, Esther H Lips, Marjanka K Schmidt, on behalf of the Grand Challenge PRECISION consortium.
BMJ 2023:383 , Published 30 October 2023

Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial - European Journal of Cancer (ejcancer.com)
R.S.J.M. Schmitz, E.G. Engelhardt, M.A. Gerritsma, C.M.T. Sondermeijer, E. Verschuur, J. Houtzager, R. Griffioen, V. Retèl, N. Bijker, R.M. Mann, F. van Duijnhoven, J. Wesseling, E.M.A. Bleiker, Grand Challenge PRECISION Consortium
European Journal of Cancer aug 2023

The successful patient-preference design for the LORD-trial to test whether active surveillance for low-risk Ductal Carcinoma In Situ is safe.
R. Schmitz, C. Sondermeijer, V. van der Noort, Ellen G. Engelhardt, M. Gerritsma, E. Verschuur, M. van Oirsouw, Eveline M.A. Bleiker, Nina Bijker, R. Mann, Frederieke van Duijnhoven, Jelle Wesseling.
November 2022, European Journal of Cancer 175:S3-S4

112P Patients' knowledge about ductal carcinoma in situ
Ellen G. Engelhardt, R. Schmitz, M. Gerritsma, C. Sondermeijer, E. Verschuur-van der Voort, M. van Oirsouw, Valesca P. Retèl , Frederieke van Duijnhoven, Jelle Wesseling, Eveline M.A. Bleiker.
May 2022. Annals of Oncology 33:S176

Prediction models and decision aids for women with ductal carcinoma in situ: a systematic literature review.
Renée S.J.M.Schmitz, Erica A. Wilthagen, Frederieke van Duijnhoven, Marja van Oirsouw, Ellen Verschuur, Thomas Lynch, Rinaa S. Punglia, E. Shelley Hwang, Jelle Wesseling, Marjanka K. Schmidt, Eveline M. A. Bleiker Ellen G. Engelhardt and Grand Challenge PRECISION Consortium.
Cancers, 2022 , 14, 3259

Preferences of Treatment Strategies among Women with Low-Risk DCIS and Oncologists

Danalyn Byng,Valesca P. Retèl, Ellen G. Engelhardt, Catharina G. M. Groothuis-Oudshoorn, Janine A. van Til, Renée S. J. M. Schmitz, Frederieke van Duijnhoven, Jelle Wesseling
Cancers 2021, 13(16), 3962

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study
Lotte E. Elshof a,b,c, Konstantinos Tryfonidis d, Leen Slaets e, A. Elise van Leeuwen-Stok f, Victoria P. Skinner a, Nicolas Dif g, Ruud M. Pijnappel h, Nina Bijker i, Emiel J.Th. Rutgers a, Jelle Wesseling b,j,⇑
European Journal of Cancer (2015) 51, 1497–1510

The LORD trial: A randomized, non-inferiority trial, between active surveillance versus standard treatment in patients with low risk ductal carcinoma in situ
Lotte E Elshof, Konstantinos Tryfonidis, Leen Slaets, A Elise van Leeuwen-Stok, Nicolas Dif, Victoria P Skinner, Claudette E Loo, Gonneke Warnars, Eveline Bleiker, Ruud M Pijnappel, Nina Bijker5, Emiel JTh Rutgers and Jelle Wesseling,
Abstract SABCS 2014, Program Number: OT3-6-01

BOOG 2014-05 / INFLAME
Clinicopathological characterization of inflammatory breast cancer in the Netherlands: First results of the prospective INFLAME registry
SABCS 2021 abstract P1-24-03 van Geel JJL

Presentatie Bossche Mammadagen 2021

Inflammatoir mammacarcinoom: belang voor de huisartspraktijk.
Schröder CP, van der Woude GF, Jansen L, Martens J, Wesseling J, Sonke G.
Huisarts & Wetenschap 2017; 8: 404-407.

Immune cell type fractions and gene expression in inflammatory breast cancer
Bense R, de Vries EGE, Fehrmann R, Schröder CP. Oral poster presentation by C.P. Schröder on July 10, 2016.
5th International Inflammatory Breast Cancer Conference, Harvard Medical School, Boston, U.S.A.

BOOG 2015-01 / MONARCH-3
Abemaciclib Plus Fulvestrant or Nonsteroidal Aromatase Inhibitor in Participants With HR+, HER2- Breast Cancer – A Pooled Analysis of the Endocrine Therapy-Naïve Participants With Measurable Disease in MONARCH 2 and MONARCH 3
SABCS 2021 abstract P1-18-21 Goetz MP, et al. Presented at: American Society of Clinical Oncology, June 1-5, 2018; Chicago, IL. USA.

BOOG 2015-02 / MONALEESA-3
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2− advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials
Hart et al.
Eur J Cancer 217 (2025) 115225

Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Prat et al
Clinical Cancer Research 2024

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2– advanced breast cancer receiving first-line ribociclib plus fulvestrant
P. Neven G.S. Sonke et al.
Breast Cancer Research (2023) 25:103;

Efficacy, safety, and quality of life with ribociclib + endocrine therapy in elderly patients with HR+/HER2– advanced breast cancer across the MONALEESA-2, -3, and -7 trials
Hart et al
SABCS 2023; #PS02-01

Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapyusing baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
André et al
P5-02-14 SABCS 2022

Pooled gene expression analysis and association with treatment response in patients with HR+/HER2–advanced breast cancer in the MONALEESA-2, -3, and -7 trials
Bardia et al PD17-08
SABCS 2022

Pooled analysis of post-progression treatments after first-line ribociclib + endocrine therapy in patients with HR+/HER2– advanced breast cancer in the MONALEESA-2, -3, and -7 studies
Hamilton et al P4-01-42
SABCS 2022

Updated Overall Survival Results From the First-Line Population in the Phase III MONALEESA-3 Trial of Postmenopausal Patients With HR+/HER2– Advanced Breast Cancer Treated With Ribociclib + Fulvestrant [oral]. ESMO breast 2022 Neven (LBA4)

Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2– advanced breast cancer
SABCS 2021 abstract GS2-00 Carey

Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies
SABCS 2021 abstract PD2-05 Prat

Analysis of first-line (1L) patients (pts) with de novo disease vs late relapse and all pts with vs without prior chemotherapy (CT) in the MONALEESA-3 (ML-3) trial
SABCS 2021 abstract P1-18-11 De Laurentiis

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
D J Slamon , P Neven , S Chia , G Jerusalem , M De Laurentiis , S Im , K Petrakova , G Valeria Bianchi, M Martín , A Nusch, G S Sonke, L De la Cruz-Merino, J T Beck, Y Ji, C Wang, U Deore, A Chakravartty, J P Zarate, T Taran, P A Fasching
Ann Oncol.2021 Aug;32(8):1015-1024. doi: 10.1016/j.annonc.2021.05.353. Epub 2021Jun 5

Updated overallsurvival (OS) results from the phase III MONALEESA-3trial of postmenopausal patients (pts) with HR+/HER2advanced breast cancer (ABC) treated w ith fulvestrant (FUL) ± ribociclib (RIB).
Dennis J. Slamon, Patrick Neven, Stephen K. L. Chia, Guy Heinrich Maria Jerusalem, Michelino De Laurentiis, Seock-Ah Im, Katarina Petrakova, Giulia Valeria Bianchi, Miguel Martin, Arnd Nusch, Gabe S. Sonke, Luis de la Cruz-Merino, J. Thaddeus Beck, Craig Wang, Uday Deore, Arunava Chakravartty, Juan Pablo Zarate, Tetiana Taran, Peter A. Fasching
2021 by American Society of Clinical Oncology

Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies
Prat A, Chaudhury A. et al.
SABCS 2020 Presentation GS1-04.

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G.
J Clin Oncol. 2018 Aug 20;36(24):2465-2472

BOOG 2015-03 / POSITIVE
Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
Dr. Hatem A Azim Jr et al
J Clin Oncol , 2024 Aug 10;42(23):2822-2832. doi: 10.1200/JCO.23.02292. Epub 2024 May 29.

Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial.
Peccatori FA, et al**.**
ESMO 2024 Oral presentation Abstract 18140

Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy lead
Dr. Hatem A Azim Jr
SABCS 2023 als een oral presentation. POSITIVE abstract #1571477

Interrupting Endocrine Therapy to Attempt Pregnancy After Breast Cancer
Ann H Partridge, Samuel M Niman, Monica Ruggeri, Fedro A Peccatori, Hatem A Azim Jr, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna Barbro Sætersdal, Judith R Kroep, Audrey Mailliez, Ellen Warner, Virginia F Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong Eon Lee, Janice M Walshe, Manuel Ruíz Borrego, Halle CF Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana

Susnjar, Fatima Cardoso, Karen L Smith, Teresa Ferreiro, Karin Ribi, Kathryn Ruddy, Roswitha Kammler, Sarra El-Abed, Giuseppe Viale, Martine Piccart, Larissa A Korde, Aron Goldhirsch†, Richard D Gelber, Olivia Pagani, for International Breast Cancer Study Group
NEJM 2023 May 4;388(18):1645-1656.

Who are the women enrolled in the POSITIVE Trial: a global study to support young hormone receptor positive breast cancer survivors desiring pregnancy?
Ann H Partridge, Samuel M Niman, Monica Ruggeri, Fedro A Peccatori, Hatem A Azim Jr, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna Barbro Sætersdal, Judith R Kroep, Audrey Maillez, Ellen Warner, Virginia F Borges, Frederic Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Hideko Yamauchi, Jeong Eon Lee, Janice M Walshe, Manuel Ruíz Borrego, Halle CF Moore, Christobel Saunders, Fatima Cardoso, Snezana Susnjar, Vesna Bjelic-Radisic, Karen L Smith, Martine Piccart, Larissa A Korde, Aron Goldhirsch, Richard D Gelber, Olivia Pagani
Breast, 2021 Aug 3;59:327-338.

Estimation of Historical Control Rate for a Single Arm De-escalation Study – Application to the POSITIVE Trial.
Sun Z, Niman SM, Pagani O, Partridge AH, Azim HA, Peccatori FA, Ruggeri M, Di Leo A, Colleoni M, Gelber RD, Regan MM; POSITIVE Steering Committee and Investigators.
Breast 2020;53:1-7. doi: 10.1016/j.breast.2020.05.012 Epub 2020 Jun 2. (IBCSG 48-14/ BIG 8-13/ Alliance A221405) (Journal Impact Factor 3.494).

Baseline characteristics of women enrolled in the POSITIVE trial (pregnancy outcome and safety of interrupting therapy for women with endocrine responsIVE breast cancer)
Ann H Partridge, Samuel M Niman, Monica Ruggeri, Fedro A Peccatori, Hatem A Azim, Jr, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna Barbro Satersdal, Judith Kroep, Ellen Warner, Virginia F Borges, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Hideko Yamauchi, Jeong Eon Lee, Janice M Walshe, Manuel Ruiz Borrego, Halle CF Moore, Christobel Saunders, Fatima Cardoso, Snezana Susnjar, Vesna Bjelic-Radisic, Karen L Smith, Martine Piccart, Larissa A Korde, Aron Goldhirsch, Richard D Gelber and Olivia Pagani. POSITIVE Investigators,
International Breast Cancer Study Group, Alliance for Clinical Trials in Oncology, Breast International Group, North American Breast Cancer Group, Bern, Switzerland
SABCS 2020 Abstract PS12-17

Behandelpauze om zwanger te raken. Anti-hormonale therapie veilig onderbreken?
J.R. Kroep
B-proefd BVN 2018 nr 21

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?
Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, Kaufman B, Paluch-Shimon S, Gewefel H, Gallerani E, Abulkhair OM, Pistilli B, Warner E, Saloustros E, Perey L, Zaman K, Rabaglio M, Gelber S, Gelber RD, Goldhirsch A, Korde L, Azim HA Jr, Partridge AH.
Breast. 24:201-207, 2015 (IBCSG 48-14) (Journal impact factor 2.381).

BOOG 2016-01 / TOP-1
Minder onnodige bestraling bij ouderen. Tailored treatment for Older Patients
Dr. Gerrit-Jan Liefers

B-proefd BVN 2016 nr 18

De behandeling van oudere vrouwen met borstkanker. De-escalatie in de oncologie
Astrid N. Scholten, Carolien P. Schröder, Sjoerd G. Elias en Gerrit Jan Liefers
Ned Tijdschrift Geneeskunde. 2021;165:D5626

BOOG 2016-02 / PALLAS
Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer
Metzger O, Ballman KV, Gnant M, et al.
JCO. 2024;42(16_suppl):538-538. doi: 10.1200/JCO.2024.42.16_suppl.538

Racial and Ethnic Differences in Clinical Outcomes among North American Patients with Hormone Receptor-Positive, HER2-negative, Early Breast Cancer in the PALLAS Trial (AFT-05)
SABCS 2023 (PO3-02-05)
Cancer Research, Vol 84, Issue 9_supl. PO3-02-05

The impact of drug-drug interactions between palbociclib and proton pump inhibitors on clinical outcomes of patients with hormone receptor positive, HER2-negative, early breast cancer: an exploratory analysis of the PALLAS study
SABCS 2023 (PO1-01-08)
Cancer Research, Vol 84, Issue 9_supl. PO1-01-08

Clinical characterization, prognostic and predictive values of HER2-low in early breast cancer in the PALLAS trial
SABCS 2023 (PO1-01-13)
Cancer Research, Vol 84, Issue 9_supl. PO1-01-13

Protocol-defined biomarker analysis in the PALLAS adjuvant trial (AFT-05; ABCSG-42): Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer
SABCS 2023 (GS03-07)
Cancer Research, Vol 84, Issue 9_supl. GS03-07

Impact of Body Mass Index on treatment and outcomes in early hormone receptor[1]positive breast cancer patients receiving endocrine therapy with or without palbociclib in the PALLAS trial
ASCO 2023 poster

Development and validation of a composite biomarker predictive of Palbociclib + endocrine treatment benefit in early breast cancer: PENELOPE-B and PALLAS trials
SABCS 2022 poster session

Impact of Body Mass Index on treatment and outcomes in early hormone receptor positive breast cancer patients receiving endocrine therapy with or without palbociclib in the PALLAS trial
ASCO 2022 poster

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Gnant, M. et al on behalf of the PALLAS group and investigators
Journal of Clnical Oncology. 2021; 40(3)

Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial
SABCS abstract 2021 GS1-07 Gnant M

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
Erica L Mayer et al
Lancet Oncology, February 2021

Treatment exposure and discontinuation in the PALLAS trial: PALbociclib CoLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for HR+/HER2- early breast cancer
Erica L. Mayer, Christian Fesl, Amylou Dueck, Michael Gnant, Angela DeMichele, on behalf of the PALLAS study team.
SABCS 2020 Abstract PD2-03

BOOG 2017-01 / NEOLBC
The use of ribociclib letrozole combination as an alternative for neoadjuvant chemotherapy in selected patients with early luminal breast cancer (BOOG 2017-01)
De Groot AF et al.
SABCS 2022 poster

CDK4/6 inhibition in early and metastatic breast cancer: A review
de Groot AF, Kuijpers CJ, Kroep JR
Cancer Treat Rev. 60:130-138, 2017

BOOG 2017-03 / SONIA
Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer.
S M Buijs, M I Mohmaed Ali, E Oomen-de Hoop, C L Braal, N Wortelboer, A van Ommen-Nijhof, G S Sonke, I R Konings, A Jager, N Steeghs, H Siebinga, R H J Mathijssen, A D R Huitema, S L W Koolen.
ESMO Open. 2025;10(3):104290.

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.
Gabe S Sonke, Annemiek van Ommen-Nijhof, Noor Wortelboer, Vincent van der Noort, Astrid C P Swinkels, Hedwig M Blommestein, Cristina Guerrero Paez, Linda Mol, Aart Beeker, Karin Beelen, Lisanne C Hamming, Joan B Heijns, Aafke H Honkoop, Paul C de Jong, Quirine C van Rossum-Schornagel, Christa van Schaik-van de Mheen, Jolien Tol, Cathrien S Tromp-van Driel, Suzan Vrijaldenhoven, A Elise van Leeuwen-Stok, Inge R Konings, Agnes Jager and the SONIA Study Consortium.
Nature. 2024;636(8042):474-480.

Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03).
N. Wortelboer, S. Kent, I.R. Konings, A. Van Ommen-Nijhof, V. van der Noort, E. van den Pol, C. Guerrero Páez, M. van Bekkum, H.J. Droogendijk, F. Erdkamp, D. Houtsma, H.M. Oosterkamp, A. van der Padt-Pruijsten, E.J. Siemerink, J. Tol, A.A. van Zweeden, A.E. van Leeuwen-Stok, G.S. Sonke, A. Jager, H.M. Blommestein,

Annals of Oncology, Vol 35, Supplement 2, S364; Abstract ESMO 2024 352P

Palbociclib exposure in relation to response and toxicity in patients with advanced breast cancer. S.M. Buijs, M.I. Mohmaed Ali, E. Oomen-de Hoop, C.L. Braal, N. Wortelboer, A. Van Ommen-Nijhof, G.S. Sonke, I.R. Konings, A. Jager, N. Steeghs, H. Siebinga, R.H. Mathijssen, A.D.R. Huitema, S.L. Koolen,
Annals of Oncology, Vol 35, Supplement 2, S369; Abstract ESMO 2024 363

Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trial.
M. Luijendijk, P. Lee Meeuw Kjoe, N. Wortelboer, A. Van Ommen – Nijhof, J. Agelink van Rentergem, I. Vermeulen, I. Konings, A. Jager, G. S. Sonke, E. van der Wall, S. B. Schagen,
Journal of Clinical Oncology, Vol 42, Supplement 16, S1016; Abstract ASCO 2024

Circulating tumor DNA dynamics in the first treatment line of the SONIA trial,
E. M Jongbloed, S. Stella, L. van Bergen, C. Beaufort, J. Helmijr, V. de Weerd, F. Erdkamp, J. Heijns, Y. Kamm, A. van Riel, Q. van Rossum-Schornagel, Maurice Jansen, I. R. Konings, G. S.Sonke, J.W.M. Martens, A. Jager, S. M Wilting,
AACR Cancer Res 2024, Vol 84, Supplement 9; Abstract SABCS 2023 PO2-14-06

Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
Gabe S Sonke, Annemiek Van Ommen - Nijhof, Noor Wortelboer, ..., Agnes Jager Md
June 2023 Journal of Clinical Oncology 41(17_suppl):LBA1000-
ASCO 2023 abstract LBA1000 DOI:10.1200/JCO.2023.41.17_suppl.LBA1000

Doelmatigheidsonderzoek naar dure geneesmiddelen: Meer bereiken met lagere kosten
Van Ommen-Nijhof A, Retèl VP, Konings IR, Sonke GS
Ned Tijdschr Geneeskd. 2022;166:D6527

A revolving research fund to study efficient use of expensive drugs: big wheels keep on turning
Van Ommen-Nijhof A, Retèl VP, van den Heuvel M, Jager A, van Harten WH, Sonke GS;
Ann Oncol. 2021 Aug 13:S0923-7534(21)03977-6,
https://www.annalsofoncology.org/article/S0923-7534(21)03977-6/fulltext

Overzichtsartikel CDK4/6-remmers bij borstkanker & samenvatting SONIA-studie in NTvO, juli 2019

Journal scan MONALEESA-7 in NTvO, november 2019

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
van Ommen-Nijhof A1, Konings IR2, van Zeijl CJJ2, Uyl-de Groot CA3, van der Noort V1, Jager A4, Sonke GS5; SONIA study steering committee.
BMC Cancer. 2018 Nov 20;18(1):1146. doi: 10.1186/s12885-018-4978-1.

Selecting the optimal position of CDK4/6 inhibitors in hormone-receptor-positive advanced breast cancer – the BOOG 2017-03 SONIA study

Annemiek van Ommen – Nijhof1, Anna van der Voort1, Inge R. Konings2, Agnes Jager3, Gabe S. Sonke1; on behalf of the SONIA investigators and the Dutch Breast Cancer Research Group (BOOG) *Posterpresentatie SABCS 2018 Session 'trial in progress'*

BOOG 2017-04 / BYLIEVE
SGLT2 inhibition improves PI3Kα inhibitor–induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials
Borrego et al
Breast Cancer Research and Treatment (2024) 208:111–121

A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer
Rodón et al.
Breast Cancer Research (2024) 26:36

Effect of alpelisib dose modification for AE management on progression-free survival and treatment duration in SOLAR-1 and BYLieve clinical trials
Rugo et al
SABCS 2023; #PO2-04-10

Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study
Chia et al poster 1078 *ASCO 2023*

Long-term (LT) and very-long-term (VLT) disease control in patients (pts) from BYLieve study Cohort A with PIK3CA-mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)
SABCS 2022 / Rugo et al, PD13-06

Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From BYLieve Study Cohorts A and B
Juric et al P4-09-12 SABCS 2022

Alpelisib + endocrine therapy (ET) in patients with HR+, HER2-, PIK3CA-mutated advanced breast cancer (ABC): Baseline biomarker analysis and PFS by duration of prior CDK4/6i therapy in the BYLieve study. ASCO 2022 poster Juric (#1018)

Alpelisib (ALP) + Endocrine Therapy (ET) in Patients With PIK3CA-Mutated, Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–) Advanced Breast Cancer (ABC): Subgroup Analyses From the BYLieve Study Cardoso et al. (175P) Fatima Cardoso. ESMO breast 2022

Effectiveness of Alpelisib + Fulvestrant Compared With Real-World Standard Treatment Among Patients With HR+, HER2–, PIK3CA-Mutated Breast Cancer
Turner S. et al.
The Oncologist 2021; 9999;

Alpelisib + fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with chemotherapy or endocrine therapy: BYLieve Cohort C results
SABCS 2021 abstract PD13-05 Rugo

Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial
SABCS 2021 abstract PD15-01 Turne

Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A
SABCS 2021 abstract P1-18-03 Ciruelos

Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve
SABCS 2021 abstract P1-18-08 Chia

Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study
SABCS 2021 abstract P5-13-03 Juric

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Rugo, Hope S et al.
The Lancet Oncology, Volume 22, Issue 4, 489 - 498

Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
Rugo HS, et al
SABCS 2020 Poster PD2-07

Real-World Effectiveness of Alpelisib + Fulvestrant Compared With Standard Treatment Among Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, PIK3CA-Mutated Advanced Breast Cancer in the Post-CDK4/6 Inhibitor Setting
Turner S. et al
ESMO 2020. Poster 309P

Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results.
Hope S. Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruiz Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric, Nicholas C. Turner, Nickolas Sophos, Juan Pablo Zarate, Christina Arce, Yu-Ming Shen, Stephen K. L. Chia; .
ASCO Virtual Meeting, 29-31 May 2020, Abstract 1006.
Journal of Clinical Oncology: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1006

BOOG 2018-01 / TRAIN-3
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
van der Voort A, Louis FM, van Ramshorst MS, Kessels R, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJ, Kuijer PM, Scholten AN, Wesseling J, Vrancken Peeters MJTFD, Mann RM, Sonke GS; On behalf of the Dutch Breast Cancer Research Group (BOOG)
The Lancet Oncology, Volume 25, Issue 5, 603 - 613

Image-guided de-escalation of neoadjuvant chemotherapy in HER2-positive breast cancer: the TRAIN-3 study.
van der Voort A, van Ramshorst MS, Dezentjé VO, van der Steeg WA, Winter-Warnars GAO, Schipper RJ, Scholten AN, Wesseling J, van Werkhoven ED, van Duijnhoven F, Vrancken Peeters MJTFD, Sonke GS; On behalf of the Dutch Breast Cancer Research Group (BOOG)
SABCS 2018 poster presentation abstract number 1079

SABCS 2022 poster presentation

BOOG 2019-01 / TIBET
Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial
Guchelaar, Niels A.D. et al.
eClinicalMedicine, Volume 80, 103065
doi: 10.1016/j.eclinm.2024.103065

BOOG 2020-02 / AMEERA-5
AMEERA-5 : A randomized, doubleblind phase 3 study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer
Aditya Bardia , Javier Cortes , Sara Hurvitz , Suzette Delaloge , Hiroji Iwata , Zhi-Ming Shao , Dheepak Kanagavel , Patrick Cohen, Qianying Liu, Sylvaine Cartot-Cotton, Vasiliki Pelekanou*, Joyce O'Shaughnessy
Posterpresentatie SABCS 2021

BOOG 2020-03 / SELECT
Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index
Max A. A. Ragusi, Claudette E. Loo, Bas H. M. van der Velden, Jelle Wesseling, Sabine C. Linn, Regina G. Beets-Tan, Sjoerd G. Elias & Kenneth G. A. Gilhuijs

Eur Radiol 30, 6740–6748 (2020), https://doi.org/10.1007/s00330-020-07058-3

BOOG 2021-01 / SEQUEL BREAST

SEQUence of Endocrine therapy in advanced Luminal Breast cancer (SEQUEL-Breast):A phase 2 study on fulvestrant beyond progression in combination with alpelisib for PIK3CA-mutated, HR+ HER2- advanced breast cancer

SABCS 2022 poster

BOOG 2021-04 TROPION-Breast 01

Abstract OT1-03-04: Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators' choice of chemotherapy in previously-treated, inoperable or metastatic HR+/HER2– breast cancer: TROPION-Breast01

Bardia, A. et al.

Cancer Research 2023;83 Suppl 5:OT1-03-04

LBA11 - Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial

Bardia A et al.

Annals of Oncology (2023) 34 (suppl_2):S1264-5

TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer

Bardia A et al.

Future Oncology 2023:10.2217/fon-2023-0188

https://www.futuremedicine.com/doi/10.2217/fon-2023-0188

275TiP ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC)

Bardia, A. et al.

Annals of Oncology 2022, Volume 33, S663 - S664

BOOG 2022-03 / ALPHABET

A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer., Pérez-Fidalgo JA, Criscitiello C, Carrasco E, et all.

Future oncology, vol. 18, no. 19. Published Online:25 Apr 2022. https://doi. org/10.2217/fon-2022-0045 5 May 2022, 25 April 2022.

BOOG 2021-03 / EMBER-3

EMBER-3: A Randomized Phase 3 Study of LY3484356, a Novel, Oral Selective Estrogen Receptor Degrader vs Investigator's Choice of Endocrine Therapy of Either Fulvestrant or Exemestane, in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine-Based Therapy

SABCS 2021 abstract OT2-11-01 Komal Jhaveri

BOOG 2022-02 / DESCARTES

De DESCARTES-Studie: De-escalatie van radiotherapie bij borstkanker patiënten met een complete pathologische respons na neoadjuvante systemische therapie

drs. J.P. van Olmen , drs. A.K.E. van Hemert , prof. dr. L.J. Boersma , dr. C.A. Drukker , dr. E.G. Engelhardt , dr. J.H. Maduro , dr. N.S. Russell , prof. dr. E.J.Th. Rutgers , dr. J. Tol , prof. dr. M.T.F.D. Vrancken Peeters , dr. F.H. van Duijnhoven
Nederlands Tijdschrift voor Oncologie, 2022;19:266–9

BOOG 2022-04 / NABOR
Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design.
Klaassen-Dekker A, Drossaert CHC, Van Maaren MC, Van Leeuwen-Stok AE, Retel VP, Korevaar JC, Siesling S.
*(2023) BMC Cancer **23***, 1112. https://doi.org/10.1186/s12885-023-11504-y

BOOG 2023-02 / TREAT ctDNA
338TiP - EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA). Michail Ignatiadis, Emmanouil Saloustros, Ana Joaquim, Jose G. Casas, Catherine M. Kelly, Evangelia Razis, Matteo Lambertini, Theodoros Foukakis, Matthias Fehr, Catharina W. Menke-van der Houven van Oordt, Thayane Antoniolli Crestani, Sonia Pernas Simon, Barbara Bussels, Marianne Hanssens, Patrick Neven, Eleni Xenophontos, Thomas Meyskens, François Clément Bidard, Coralie Poncet, Wolfgang Janni.
Abstract ESMO september 2024

Patientenparticipatie
Patients' perceptions on breast cancer clinical trials
S. Tax., J.E. Elberse, C.A.C.M. Pittens, A.E. van Leeuwen-Stok, M. Schrieks, J.E.W. Broerse
Abstract ECCO 2013

How breast cancer patients value partaking in non-commercial clinical trials
C.A.C.M. Pittens, J.E. Elberse, A.E. Van Leeuwen-Stok, M. Jonker, J.E.W. Broerse
Submitted European Journal of Cancer Care, 2013

Patient involvement in breast cancer clinical trials: what do patients and professionals want?
C.A.C.M. Pittens, J.E. Elberse, A. E. Van Leeuwen-Stok, S. Tax, J.E.W. Broerse
Submitted Health Expectations, 2013

Wat wil de patient als het om onderzoek gaat? Interview met E. van der Wall,
Medische Oncologie dec 2012

Active Patient Involvement in Breast Cancer Clinical Trials, C.A.C.M. Pittens,
Presentatie 6th Clinical Forum Congress, 8-10 oktober 2012

Patients' Perceptions On Breast Cancer Clinical Trials
C.A.C.M. Pittens, J.E. Elberse, S. Tax, A.E. van Leeuwen-Stok, M. Schrieks, M. Jonker, J.E.W. Broerse
Abstract EBCC-8, 2012